Bellmunt Molins, Joaquin
eCommons Login: JB208
first name: Joaquin
last name: Bellmunt Molins
coauthor of: Choueiri, Toni
coauthor of: Martin-Doyle, William
coauthor of: Signoretti, Sabina
coauthor of: Kwiatkowski, David
coauthor of: Van Allen, Eliezer
full name: Joaquin Bellmunt Molins, M.D.
has faculty rank: Full Professor
has network: selected publications
has network: research areas
has network: coauthor of
has network: similar to
Person ID: 72828
person in primary position: Professor of Medicine
similar to: Choueiri, Toni
similar to: Efstathiou, Jason
similar to: Mossanen, Matthew
similar to: McDermott, David
similar to: McGregor, Bradley
type: Agent
type: Person
selected publications: Authorship 1822577
selected publications: Authorship 1843252
selected publications: Authorship 1841636
selected publications: Authorship 1662620
selected publications: Authorship 1660392
selected publications: Authorship 1791980
selected publications: Authorship 1784173
selected publications: Authorship 1774087
selected publications: Authorship 1788697
selected publications: Authorship 1361130
selected publications: Authorship 1339200
selected publications: Authorship 1282400
selected publications: Authorship 1148866
selected publications: Authorship 1165388
selected publications: Authorship 1158491
selected publications: Authorship 1143396
selected publications: Authorship 1149819
selected publications: Authorship 1152278
selected publications: Authorship 1150155
selected publications: Authorship 1148826
selected publications: Authorship 1150404
selected publications: Authorship 1141806
selected publications: Authorship 1139333
selected publications: Authorship 1127885
selected publications: Authorship 1122452
selected publications: Authorship 1121148
selected publications: Authorship 1118267
selected publications: Authorship 1104805
selected publications: Authorship 1093887
selected publications: Authorship 1100293
selected publications: Authorship 1164035
selected publications: Authorship 1082565
selected publications: Authorship 1090301
selected publications: Authorship 1089798
selected publications: Authorship 1087385
selected publications: Authorship 1085578
selected publications: Authorship 1080444
selected publications: Authorship 1081307
selected publications: Authorship 1077656
selected publications: Authorship 1074125
selected publications: Authorship 1072594
selected publications: Authorship 1069547
selected publications: Authorship 1071330
selected publications: Authorship 1064603
selected publications: Authorship 1153587
selected publications: Authorship 1065699
selected publications: Authorship 1063184
selected publications: Authorship 1046455
selected publications: Authorship 1054590
selected publications: Authorship 1051093
selected publications: Authorship 1053892
selected publications: Authorship 1046582
selected publications: Authorship 1000817
selected publications: Authorship 1045783
selected publications: Authorship 1040805
selected publications: Authorship 1090502

eCommons Login
tag name: catalyst:eCommonsLogin
type: DatatypeProperty

coauthor of
tag name: prns:coAuthorOf
type: ObjectProperty

Faculty Rank
type: Class

full name
tag name: prns:fullName
type: DatatypeProperty

author list
tag name: prns:hasAuthorList
type: DatatypeProperty

has faculty rank
tag name: prns:hasFacultyRank
type: ObjectProperty

has network
tag name: prns:hasNetwork
type: ObjectProperty

published in
tag name: prns:hasPublicationVenue
type: DatatypeProperty

information resource reference
tag name: prns:informationResourceReference
type: DatatypeProperty

is primary position
tag name: prns:isPrimaryPosition
type: DatatypeProperty

latitude
tag name: prns:latitude
type: DatatypeProperty

longitude
tag name: prns:longitude
type: DatatypeProperty

photo
tag name: prns:mainImage
type: ObjectProperty

maximum weight
tag name: prns:maxWeight
type: DatatypeProperty

journal title abbreviation
tag name: prns:medlineTA
type: DatatypeProperty

MeSH DescriptorUI
tag name: prns:meshDescriptorUI
type: DatatypeProperty

MeSH semantic group name
tag name: prns:meshSemanticGroupName
type: DatatypeProperty

minimum weight
tag name: prns:minWeight
type: DatatypeProperty

number of authors
tag name: prns:numberOfAuthors
type: DatatypeProperty

number of connections
tag name: prns:numberOfConnections
type: DatatypeProperty

number of publications
tag name: prns:numberOfPublications
type: DatatypeProperty

Person ID
tag name: prns:personId
type: DatatypeProperty

person in primary position
tag name: prns:personInPrimaryPosition
type: ObjectProperty

position in department
tag name: prns:positionInDepartment
type: ObjectProperty

position in division
tag name: prns:positionInDivision
type: ObjectProperty

predicate node
tag name: prns:predicateNode
type: ObjectProperty

publication date
tag name: prns:publicationDate
type: DatatypeProperty

similar to
tag name: prns:similarTo
type: ObjectProperty

sort order
tag name: prns:sortOrder
type: DatatypeProperty

uniqueness weight
tag name: prns:uniquenessWeight
type: DatatypeProperty

year
tag name: prns:year
type: DatatypeProperty

Academic Article
type: Class

Article
type: Class

Document
type: Class

PubMed Identifier
tag name: bibo:pmid
type: DatatypeProperty

Address
type: Class

address line 1
tag name: vivo:address1
type: DatatypeProperty

address line 2
tag name: vivo:address2
type: DatatypeProperty

address line 3
tag name: vivo:address3
type: DatatypeProperty

city
tag name: vivo:addressCity
type: DatatypeProperty
type: FunctionalProperty

postal code
tag name: vivo:addressPostalCode
type: DatatypeProperty
type: FunctionalProperty

state or province
tag name: vivo:addressState
type: DatatypeProperty
type: FunctionalProperty

selected publications
tag name: vivo:authorInAuthorship
type: ObjectProperty

author rank in publication
tag name: vivo:authorRank
type: DatatypeProperty
type: FunctionalProperty

Authorship
type: Class

Department
type: Class

Division
type: Class

research areas
tag name: vivo:hasResearchArea
type: ObjectProperty

HR job title
tag name: vivo:hrJobTitle
type: DatatypeProperty

Information Resource
type: Class

linked author
tag name: vivo:linkedAuthor
type: ObjectProperty

linked information resource
tag name: vivo:linkedInformationResource
type: ObjectProperty

mailing address
tag name: vivo:mailingAddress
type: ObjectProperty

positions
tag name: vivo:personInPosition
type: ObjectProperty

Position
type: Class

position in organization
tag name: vivo:positionInOrganization
type: ObjectProperty

preferred title
tag name: vivo:preferredTitle
type: DatatypeProperty
type: FunctionalProperty

predicate
tag name: rdf:predicate
type: ObjectProperty

type
tag name: rdf:type
type: ObjectProperty

label
tag name: rdfs:label
type: DatatypeProperty

Concept
type: Class

Agent
type: Class

first name
tag name: foaf:firstName
type: DatatypeProperty
type: FunctionalProperty

last name
tag name: foaf:lastName
type: DatatypeProperty
type: FunctionalProperty

Organization
type: Class

Person
type: Class

Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line.
PubMed Identifier: 10834027
author list: Cos J, Bellmunt J, Soler C, Ribas A, Lluis JM, Murio JE, Margarit C
published in: Cancer investigation
information resource reference: Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line. Cancer Invest. 2000; 18(5):429-35.
journal title abbreviation: Cancer Invest
publication date: 2000-01-01T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1046455
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.

Authorship 1046582
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.

Authorship 1045783
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/91522303

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
PubMed Identifier: 29478735
author list: Pal SK, Hoffman-Censits J, Zheng H, Kaiser C, Tayama D, Bellmunt J
published in: European urology
information resource reference: Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. Eur Urol. 2018 05; 73(5):800-806.
journal title abbreviation: Eur Urol
publication date: 2018-02-22T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
PubMed Identifier: 29423515
author list: Petrylak DP, Powles T, Bellmunt J, Braiteh F, Loriot Y, Morales-Barrera R, Burris HA, Kim JW, Ding B, Kaiser C, Fassò M, O'Hear C, Vogelzang NJ
published in: JAMA oncology
information resource reference: Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study. JAMA Oncol. 2018 Apr 01; 4(4):537-544.
journal title abbreviation: JAMA Oncol
publication date: 2018-04-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1051093
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Avelumab for the treatment of urothelial cancer.

Avelumab for the treatment of urothelial cancer.
PubMed Identifier: 29540084
author list: Rodriguez-Vida A, Bellmunt J
published in: Expert review of anticancer therapy
information resource reference: Avelumab for the treatment of urothelial cancer. Expert Rev Anticancer Ther. 2018 05; 18(5):421-429.
journal title abbreviation: Expert Rev Anticancer Ther
publication date: 2018-03-14T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1053892
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.
PubMed Identifier: 29550200
author list: Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, Gonzalez I, Castellano DE, Ozguroglu M, Carbonero IG, Flechon A, Borrega P, Guillot A, Balea BC, Le Moulec S, Esteban E, Munarriz J, Rubio G, Birtle AJ, Delanoy N, Bellmunt J, Oudard S
published in: Clinical genitourinary cancer
information resource reference: Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents. Clin Genitourin Cancer. 2018 08; 16(4):e777-e784.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2018-02-23T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations.
PubMed Identifier: 19154471
author list: Bellmunt J, Guix M
published in: BJU international
information resource reference: The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int. 2009 Mar; 103(5):572-7.
journal title abbreviation: BJU Int
publication date: 2009-03-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1054590
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.
PubMed Identifier: 29590008
author list: Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol. 2018 06 01; 36(16):1579-1587.
journal title abbreviation: J Clin Oncol
publication date: 2018-03-28T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

[Primary non-Hodgkin's lymphoma of the breast].
PubMed Identifier: 7746002
author list: Vicente P, Bellmunt J, Ruiz-Marcellan C, García A, Rovirosa A, Solé LA
published in: Medicina clinica
information resource reference: [Primary non-Hodgkin's lymphoma of the breast]. Med Clin (Barc). 1993 Sep 11; 101(7):261-3.
journal title abbreviation: Med Clin (Barc)
publication date: 1993-09-11T00:00:00
year: 1993
type: Academic Article
type: Article
type: Document
type: Information Resource

Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.
PubMed Identifier: 8687094
author list: Albanell J, Bellmunt J, Molina R, García M, Caragol I, Bermejo B, Ribas A, Carulla J, Gallego OS, Español T, Solé Calvo LA
published in: Anticancer research
information resource reference: Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res. 1996 Mar-Apr; 16(2):1027-32.
journal title abbreviation: Anticancer Res
publication date: 1996-03-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI).
PubMed Identifier: 9061063
author list: Ribas A, Bellmunt J, Albanell J, De Torres I, Bermejo B, De Torres JA, Morote J, Gallardo E, Vera R, Carulla J, Sole-Calvo LA
published in: Tumori
information resource reference: Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI). Tumori. 1996 Nov-Dec; 82(6):554-9.
journal title abbreviation: Tumori
publication date: 1996-11-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer.
PubMed Identifier: 7828134
author list: Solé LA, Albanell J, Bellmunt J, Ribas A, Gallego OS, Carulla J
published in: Cancer
information resource reference: Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer. 1995 Feb 01; 75(3):831-5.
journal title abbreviation: Cancer
publication date: 1995-02-01T00:00:00
year: 1995
type: Academic Article
type: Article
type: Document
type: Information Resource

Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
PubMed Identifier: 19201525
author list: Bellmunt J, Ribas A
published in: European urology
information resource reference: Editorial comment on: Vaccine therapy in patients with renal cell carcinoma. Eur Urol. 2009 Jun; 55(6):1342-3.
journal title abbreviation: Eur Urol
publication date: 2009-01-30T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1063184
type: Authorship
author rank in publication: 15
linked author: Bellmunt Molins, Joaquin
linked information resource: Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.

Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
PubMed Identifier: 29706503
author list: Sonpavde G, Pond GR, Rosenberg JE, Choueiri TK, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF
published in: Clinical genitourinary cancer
information resource reference: Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clin Genitourin Cancer. 2018 08; 16(4):e961-e967.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2018-04-06T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

[Epithelioid hemangioendothelioma of the liver].
PubMed Identifier: 2157928
author list: Bellmunt J, Morales S, Allende E, Solé Calvo LA
published in: Medicina clinica
information resource reference: [Epithelioid hemangioendothelioma of the liver]. Med Clin (Barc). 1990 Feb 10; 94(5):198.
journal title abbreviation: Med Clin (Barc)
publication date: 1990-02-10T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

[Metachronic squamous carcinoma of the tonsils to microcytic carcinoma of the esophagus].
PubMed Identifier: 2158605
author list: Navarro M, Morales S, Bellmunt J, Jolis L
published in: Medicina clinica
information resource reference: [Metachronic squamous carcinoma of the tonsils to microcytic carcinoma of the esophagus]. Med Clin (Barc). 1990 Jan 20; 94(2):77-8.
journal title abbreviation: Med Clin (Barc)
publication date: 1990-01-20T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
PubMed Identifier: 17280909
author list: Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS
published in: Urology
information resource reference: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007 Jan; 69(1 Suppl):62-79.
journal title abbreviation: Urology
publication date: 2007-01-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Sorafenib TARGET trial results in Spanish patients.
PubMed Identifier: 17974528
author list: Bellmunt J, González-Larriba JL, Climent MA, López-Vivanco G, Urruticoechea L, Albanell J
published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
information resource reference: Sorafenib TARGET trial results in Spanish patients. Clin Transl Oncol. 2007 Oct; 9(10):671-3.
journal title abbreviation: Clin Transl Oncol
publication date: 2007-10-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1064603
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Authorship 1065699
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: The clinical impact of using complex molecular profiling strategies in routine oncology practice.

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
PubMed Identifier: 29765151
author list: Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK
published in: British journal of cancer
information resource reference: Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer. 2018 05; 118(11):1434-1441.
journal title abbreviation: Br J Cancer
publication date: 2018-05-16T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

The clinical impact of using complex molecular profiling strategies in routine oncology practice.
PubMed Identifier: 29755651
author list: Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Odarchenko S, Perren TJ, Pienaar R, Regonesi C, Alkhayyat SS, El Kinge AR, Abulkhair O, Galal KM, Ghanem H, El Karak F, Garcia A, Ghitti G, Sadik H
published in: Oncotarget
information resource reference: The clinical impact of using complex molecular profiling strategies in routine oncology practice. Oncotarget. 2018 Apr 17; 9(29):20282-20293.
journal title abbreviation: Oncotarget
publication date: 2018-04-17T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Wilms' tumor in an adult patient.
PubMed Identifier: 2467422
author list: Palou J, Banus JM, Bellmunt J, Carulla J, Egido R
published in: Urologia internationalis
information resource reference: Wilms' tumor in an adult patient. Urol Int. 1988; 43(6):349-51.
journal title abbreviation: Urol Int
publication date: 1988-01-01T00:00:00
year: 1988
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1069547
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.

Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.
PubMed Identifier: 29848570
author list: McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088.
journal title abbreviation: Clin Cancer Res
publication date: 2018-05-30T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses.
PubMed Identifier: 22981209
author list: Wagner M, Bellmunt J, Boutros C, Bonardel G, Loriot Y, Albiges L, Massard C, Fizazi K
published in: Clinical genitourinary cancer
information resource reference: False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses. Clin Genitourin Cancer. 2013 Mar; 11(1):66-9.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2012-09-13T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1071330
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."

Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."
PubMed Identifier: 29859727
author list: Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE
published in: Urologic oncology
information resource reference: Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma." Urol Oncol. 2018 07; 36(7):345-346.
journal title abbreviation: Urol Oncol
publication date: 2018-05-30T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1074125
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis.

Authorship 1072594
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology.

Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis.
PubMed Identifier: 29926345
author list: Shi H, Yu H, Bellmunt J, Leow JJ, Chen X, Guo C, Yang H, Zhang X
published in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
information resource reference: Comparison of health-related quality of life (HRQoL) between ileal conduit diversion and orthotopic neobladder based on validated questionnaires: a systematic review and meta-analysis. Qual Life Res. 2018 Nov; 27(11):2759-2775.
journal title abbreviation: Qual Life Res
publication date: 2018-06-20T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology.
PubMed Identifier: 29893263
author list: Kanesvaran R, Le Saux O, Motzer R, Choueiri TK, Scotté F, Bellmunt J, Launay-Vacher V
published in: The Lancet. Oncology
information resource reference: Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncol. 2018 06; 19(6):e317-e326.
journal title abbreviation: Lancet Oncol
publication date: 2018-06-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
PubMed Identifier: 20553208
author list: Bellmunt J, Fishman M, Eisen T, Quinn D
published in: Expert review of anticancer therapy
information resource reference: Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010 Jun; 10(6):825-35.
journal title abbreviation: Expert Rev Anticancer Ther
publication date: 2010-06-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
PubMed Identifier: 23206856
author list: Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J
published in: European urology
information resource reference: Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr; 63(4):717-23.
journal title abbreviation: Eur Urol
publication date: 2012-11-26T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 115750
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?

Authorship 1077656
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.
PubMed Identifier: 29980530
author list: Li Q, Damish AW, Frazier Z, Liu D, Reznichenko E, Kamburov A, Bell A, Zhao H, Jordan EJ, Gao SP, Ma J, Abbosh PH, Bellmunt J, Plimack ER, Lazaro JB, Solit DB, Bajorin D, Rosenberg JE, D'Andrea AD, Riaz N, Van Allen EM, Iyer G, Mouw KW
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2019 02 01; 25(3):977-988.
journal title abbreviation: Clin Cancer Res
publication date: 2018-07-06T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
PubMed Identifier: 21056534
author list: Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F
published in: European urology
information resource reference: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011 Jan; 59(1):61-71.
journal title abbreviation: Eur Urol
publication date: 2010-10-28T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Maximizing outcomes in genitourinary cancers across the treatment continuum.
PubMed Identifier: 21382149
author list: Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A
published in: BJU international
information resource reference: Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU Int. 2011 Apr; 107 Suppl 2:1-12.
journal title abbreviation: BJU Int
publication date: 2011-04-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1064614
PubMed Identifier: 22425264
author list: Gore ME, Bellmunt J, Eisen T, Escudier B, Mickisch G, Patard J, Porta C, Ravaud A, Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, De Nigris E, Wheeler C, Kirpekar S
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. Eur J Cancer. 2012 May; 48(7):1038-47.
journal title abbreviation: Eur J Cancer
publication date: 2012-03-14T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology.

Orbital metastases from transitional-cell cancer of the urinary bladder.
PubMed Identifier: 2024382
author list: Felip E, Rovirosa MA, Salud A, Capdevila F, Bellmunt J, Giralt J
published in: Urologia internationalis
information resource reference: Orbital metastases from transitional-cell cancer of the urinary bladder. Urol Int. 1991; 46(1):82-4.
journal title abbreviation: Urol Int
publication date: 1991-01-01T00:00:00
year: 1991
type: Academic Article
type: Article
type: Document
type: Information Resource

Intermittent chemotherapy in metastatic androgen-independent prostate cancer.
PubMed Identifier: 17669140
author list: Bellmunt J, Albiol S, Albanell J
published in: BJU international
information resource reference: Intermittent chemotherapy in metastatic androgen-independent prostate cancer. BJU Int. 2007 Sep; 100(3):490-2.
journal title abbreviation: BJU Int
publication date: 2007-09-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
PubMed Identifier: 17693649
author list: Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol. 2007 Aug; 18(8):1359-62.
journal title abbreviation: Ann Oncol
publication date: 2007-08-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
PubMed Identifier: 19388982
author list: Bellmunt J, Flodgren P, Roigas J, Oudard S
published in: BJU international
information resource reference: Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int. 2009 Jul; 104(1):10-8.
journal title abbreviation: BJU Int
publication date: 2009-04-21T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
PubMed Identifier: 19757215
author list: Negrier S, Jäger E, Porta C, McDermott D, Moore M, Bellmunt J, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R
published in: Medical oncology (Northwood, London, England)
information resource reference: Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol. 2010 Sep; 27(3):899-906.
journal title abbreviation: Med Oncol
publication date: 2009-09-12T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
PubMed Identifier: 20163987
author list: Bellmunt J, Trigo JM, Calvo E, Carles J, Pérez-Gracia JL, Rubió J, Virizuela JA, López R, Lázaro M, Albanell J
published in: The Lancet. Oncology
information resource reference: Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010 Apr; 11(4):350-7.
journal title abbreviation: Lancet Oncol
publication date: 2010-02-15T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Epithelioid hemangioendothelioma of the liver with myocardial metastases.
PubMed Identifier: 2733168
author list: Bellmunt J, Allende E, Navarro M, Morales S, Sans M, Jolis L, Garcia AA, Rubio D
published in: Japanese journal of clinical oncology
information resource reference: Epithelioid hemangioendothelioma of the liver with myocardial metastases. Jpn J Clin Oncol. 1989 Jun; 19(2):153-8.
journal title abbreviation: Jpn J Clin Oncol
publication date: 1989-06-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1080444
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.

Authorship 1082565
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.

Authorship 1081307
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes.

Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
PubMed Identifier: 30017405
author list: Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF, Kulkarni GS
published in: European urology
information resource reference: Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. Eur Urol. 2018 11; 74(5):597-608.
journal title abbreviation: Eur Urol
publication date: 2018-07-13T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes.
PubMed Identifier: 29991503
author list: Rodriguez-Vida A, Perez-Gracia JL, Bellmunt J
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Clin Cancer Res. 2018 12 15; 24(24):6115-6124.
journal title abbreviation: Clin Cancer Res
publication date: 2018-07-10T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
PubMed Identifier: 30012366
author list: Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A
published in: The Journal of urology
information resource reference: Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. J Urol. 2018 12; 200(6):1207-1214.
journal title abbreviation: J Urol
publication date: 2018-09-04T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
PubMed Identifier: 21543626
author list: Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012 Feb; 23(2):406-10.
journal title abbreviation: Ann Oncol
publication date: 2011-05-04T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
PubMed Identifier: 21555688
author list: Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10; 29(17):2432-8.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-09T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Statins and the effect of BCG on bladder cancer.
PubMed Identifier: 17380586
author list: Orsola A, Cecchini L, Bellmunt J
published in: The New England journal of medicine
information resource reference: Statins and the effect of BCG on bladder cancer. N Engl J Med. 2007 Mar 22; 356(12):1276; author reply 1276-7.
journal title abbreviation: N Engl J Med
publication date: 2007-03-22T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

[Symptomatic hypomagnesemia in a patient treated with cisplatin].
PubMed Identifier: 2214911
author list: Felip E, Bellmunt J, Salud A, Capdevila F
published in: Medicina clinica
information resource reference: [Symptomatic hypomagnesemia in a patient treated with cisplatin]. Med Clin (Barc). 1990 Jun 30; 95(5):196-7.
journal title abbreviation: Med Clin (Barc)
publication date: 1990-06-30T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1077550
PubMed Identifier: 22370319
author list: Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012 Apr 01; 30(10):1107-13.
journal title abbreviation: J Clin Oncol
publication date: 2012-02-27T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.
PubMed Identifier: 22532265
author list: Sonpavde G, Bellmunt J, Schutz F, Choueiri TK
published in: Current oncology reports
information resource reference: The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep. 2012 Aug; 14(4):295-306.
journal title abbreviation: Curr Oncol Rep
publication date: 2012-08-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1085578
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.

Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.
PubMed Identifier: 30072631
author list: Bellmunt J
published in: Biomedicines
information resource reference: Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4. Biomedicines. 2018 Aug 02; 6(3).
journal title abbreviation: Biomedicines
publication date: 2018-08-02T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Diagnostic value of bronchoalveolar lavage in peripheral lung cancer.
PubMed Identifier: 8442600
author list: de Gracia J, Bravo C, Miravitlles M, Tallada N, Orriols R, Bellmunt J, Vendrell M, Morell F
published in: The American review of respiratory disease
information resource reference: Diagnostic value of bronchoalveolar lavage in peripheral lung cancer. Am Rev Respir Dis. 1993 Mar; 147(3):649-52.
journal title abbreviation: Am Rev Respir Dis
publication date: 1993-03-01T00:00:00
year: 1993
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1087385
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
PubMed Identifier: 30096301
author list: Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Weinstein JN, Kwiatkowski DJ, Lerner SP
published in: Cell
information resource reference: Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018 08 09; 174(4):1033.
journal title abbreviation: Cell
publication date: 2018-08-09T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Fatal septic thrombophlebitis due to Salmonella enteritidis.
PubMed Identifier: 2495956
author list: Navarro M, Almirante B, Bellmunt J, Jolis L
published in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
information resource reference: Fatal septic thrombophlebitis due to Salmonella enteritidis. Eur J Clin Microbiol Infect Dis. 1989 Jan; 8(1):82-3.
journal title abbreviation: Eur J Clin Microbiol Infect Dis
publication date: 1989-01-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1089798
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis.

Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis.
PubMed Identifier: 30139659
author list: Gild P, Wankowicz SA, Sood A, von Landenberg N, Friedlander DF, Alanee S, Chun FKH, Fisch M, Menon M, Trinh QD, Bellmunt J, Abdollah F
published in: Urologic oncology
information resource reference: Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis. Urol Oncol. 2018 10; 36(10):469.e1-469.e11.
journal title abbreviation: Urol Oncol
publication date: 2018-08-20T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
PubMed Identifier: 20163917
author list: Schmidinger M, Bellmunt J
published in: Cancer treatment reviews
information resource reference: Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010 Aug; 36(5):416-24.
journal title abbreviation: Cancer Treat Rev
publication date: 2010-02-16T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
PubMed Identifier: 20615828
author list: Bellmunt J, Maroto-Rey P, Trigo JM, Carles J, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L
published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
information resource reference: A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clin Transl Oncol. 2010 Jul; 12(7):503-8.
journal title abbreviation: Clin Transl Oncol
publication date: 2010-07-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.
PubMed Identifier: 20640589
author list: Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Bellmunt J, Castellano D
published in: Cancer metastasis reviews
information resource reference: Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer Metastasis Rev. 2010 Aug; 29 Suppl 1:1-10.
journal title abbreviation: Cancer Metastasis Rev
publication date: 2010-08-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1090301
type: Authorship
author rank in publication: 23
linked author: Bellmunt Molins, Joaquin
linked information resource: Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Authorship 1090502
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: The Cancer Genome Atlas Project in Bladder Cancer.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
PubMed Identifier: 30150660
author list: Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM
published in: Nature genetics
information resource reference: Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
journal title abbreviation: Nat Genet
publication date: 2018-08-27T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

The Cancer Genome Atlas Project in Bladder Cancer.
PubMed Identifier: 30168126
author list: Rodriguez-Vida A, Lerner SP, Bellmunt J
published in: Cancer treatment and research
information resource reference: The Cancer Genome Atlas Project in Bladder Cancer. Cancer Treat Res. 2018; 175:259-271.
journal title abbreviation: Cancer Treat Res
publication date: 2018-01-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

[The incidence of second neoplasms in advanced laryngeal cancer. Impact on survival].
PubMed Identifier: 8121197
author list: Rovirosa A, Bellmunt J, López A, Fernández M, Guerra M, Montagut J
published in: Medicina clinica
information resource reference: [The incidence of second neoplasms in advanced laryngeal cancer. Impact on survival]. Med Clin (Barc). 1994 Feb 05; 102(4):121-4.
journal title abbreviation: Med Clin (Barc)
publication date: 1994-02-05T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
PubMed Identifier: 22832091
author list: Calvo E, Ravaud A, Bellmunt J
published in: Cancer treatment reviews
information resource reference: What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev. 2013 Jun; 39(4):366-74.
journal title abbreviation: Cancer Treat Rev
publication date: 2012-07-23T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Prostate cancer. Multidisciplinary approach: a key to success.
PubMed Identifier: 18723370
author list: Montagut C, Albanell J, Bellmunt J
published in: Critical reviews in oncology/hematology
information resource reference: Prostate cancer. Multidisciplinary approach: a key to success. Crit Rev Oncol Hematol. 2008 Oct; 68 Suppl 1:S32-6.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2008-08-23T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Orbital metastasis, by transitional cell carcinoma of the bladder.
PubMed Identifier: 2613468
author list: Prats J, Bellmunt J, Calvo MA, Sarrias F, Toran N
published in: International urology and nephrology
information resource reference: Orbital metastasis, by transitional cell carcinoma of the bladder. Int Urol Nephrol. 1989; 21(4):389-92.
journal title abbreviation: Int Urol Nephrol
publication date: 1989-01-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Experience with sorafenib and adverse event management.
PubMed Identifier: 20399677
author list: Bellmunt J, Eisen T, Fishman M, Quinn D
published in: Critical reviews in oncology/hematology
information resource reference: Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr; 78(1):24-32.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2010-04-18T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1093887
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
PubMed Identifier: 30220708
author list: Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE
published in: British journal of cancer
information resource reference: Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018 09; 119(6):707-712.
journal title abbreviation: Br J Cancer
publication date: 2018-09-17T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
PubMed Identifier: 21205755
author list: Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8.
journal title abbreviation: J Clin Oncol
publication date: 2011-01-04T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
PubMed Identifier: 21550166
author list: Sonpavde G, Attard G, Bellmunt J, Mason MD, Malavaud B, Tombal B, Sternberg CN
published in: European urology
information resource reference: The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol. 2011 Aug; 60(2):270-8.
journal title abbreviation: Eur Urol
publication date: 2011-04-29T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1105848
PubMed Identifier: 22015057
author list: Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, González del Alba A, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C
published in: The Lancet. Oncology
information resource reference: Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011 11; 12(12):1143-50.
journal title abbreviation: Lancet Oncol
publication date: 2011-10-17T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.

A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.
PubMed Identifier: 22615059
author list: Gómez-Martín C, Salazar R, Montagut C, Gil-Martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J
published in: Investigational new drugs
information resource reference: A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs. 2013 Apr; 31(2):390-8.
journal title abbreviation: Invest New Drugs
publication date: 2012-05-22T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients.
PubMed Identifier: 23062225
author list: Bellmunt J
published in: European urology
information resource reference: Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients. Eur Urol. 2013 Feb; 63(2):198-200.
journal title abbreviation: Eur Urol
publication date: 2012-10-05T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1104805
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.

Authorship 1100293
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.

Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
PubMed Identifier: 30292628
author list: Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD
published in: Clinical genitourinary cancer
information resource reference: Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2019 Feb; 17(1):7-14.e3.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2018-09-13T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
PubMed Identifier: 30321689
author list: Carles J, Gallardo E, Doménech M, Font A, Bellmunt J, Figols M, Mellado B, Sáez MI, Suárez C, Méndez MJ, Maroto P, Luque R, de Portugal T, Aldabo R, Bonfill T, Morales-Barrera R, García J, Maciá S, Maldonado X, Foro P
published in: International journal of radiation oncology, biology, physics
information resource reference: Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. Int J Radiat Oncol Biol Phys. 2019 02 01; 103(2):344-352.
journal title abbreviation: Int J Radiat Oncol Biol Phys
publication date: 2018-10-12T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
PubMed Identifier: 9486577
author list: Ribas A, Albanell J, Solé-Calvo LA, Gallardo E, Bellmunt J, Vera R, Vidal R, Carulla J, Baselga J
published in: Cancer
information resource reference: Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma. Cancer. 1998 Mar 01; 82(5):878-85.
journal title abbreviation: Cancer
publication date: 1998-03-01T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival.
PubMed Identifier: 18707804
author list: Bellmunt J, Hautmann RE
published in: European urology
information resource reference: Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival. Eur Urol. 2008 Nov; 54(5):1192-7.
journal title abbreviation: Eur Urol
publication date: 2008-08-05T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 127149
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.

Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.
PubMed Identifier: 22609313
author list: Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, Herr H, Lechevallier E, Ribal MJ
published in: European urology
information resource reference: Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol. 2012 Aug; 62(2):290-302.
journal title abbreviation: Eur Urol
publication date: 2012-05-12T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1130636
PubMed Identifier: 8622074
author list: Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, Baselga J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol. 1996 May; 14(5):1573-80.
journal title abbreviation: J Clin Oncol
publication date: 1996-05-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.

Endobronchial metastatic disease: analysis of 32 cases.
PubMed Identifier: 8691837
author list: Salud A, Porcel JM, Rovirosa A, Bellmunt J
published in: Journal of surgical oncology
information resource reference: Endobronchial metastatic disease: analysis of 32 cases. J Surg Oncol. 1996 Aug; 62(4):249-52.
journal title abbreviation: J Surg Oncol
publication date: 1996-08-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

[Solitary cerebellar metastases: a clinical neuro-radiological study].
PubMed Identifier: 3078755
author list: Montalbán J, Molins A, Fernández JL, Romero F, Bellmunt J, Alvarez J, Codina Puiggrós A
published in: Neurologia (Barcelona, Spain)
information resource reference: [Solitary cerebellar metastases: a clinical neuro-radiological study]. Neurologia. 1988 Jan-Feb; 3(1):3-8.
journal title abbreviation: Neurologia
publication date: 1988-01-01T00:00:00
year: 1988
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1118
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients.

[Gene therapy: new prospects in the treatment of cancer].
PubMed Identifier: 7861836
author list: Ribas A, Bellmunt J
published in: Medicina clinica
information resource reference: [Gene therapy: new prospects in the treatment of cancer]. Med Clin (Barc). 1994 Dec 10; 103(20):776-9.
journal title abbreviation: Med Clin (Barc)
publication date: 1994-12-10T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.
PubMed Identifier: 8677901
author list: Bellmunt J, Ribas A, Albanell J, Bermejo B, Vera R, De Torres JA, Morote J, Lopez-Pacios MA, Banus JM, Rovirosa A, Carulla J, Sole LA
published in: American journal of clinical oncology
information resource reference: M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. Am J Clin Oncol. 1996 Aug; 19(4):344-8.
journal title abbreviation: Am J Clin Oncol
publication date: 1996-08-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 118064
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations.

[Bilateral choroidal metastasis as a form of presentation of pulmonary carcinoma].
PubMed Identifier: 8127172
author list: Vilà A, Bellmunt J, Rilo A, Saballs P
published in: Medicina clinica
information resource reference: [Bilateral choroidal metastasis as a form of presentation of pulmonary carcinoma]. Med Clin (Barc). 1994 Feb 12; 102(5):196-7.
journal title abbreviation: Med Clin (Barc)
publication date: 1994-02-12T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

Late recurrent metastasis in Wilms' tumour.
PubMed Identifier: 8202042
author list: Gallego-Melcón S, Sánchez de Toledo J, Doste D, López D, Moraga F, Rodríguez C, Vidal T, Bellmunt J
published in: Medical and pediatric oncology
information resource reference: Late recurrent metastasis in Wilms' tumour. Med Pediatr Oncol. 1994; 23(2):158-61.
journal title abbreviation: Med Pediatr Oncol
publication date: 1994-01-01T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1118267
type: Authorship
author rank in publication: 13
linked author: Bellmunt Molins, Joaquin
linked information resource: Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.
PubMed Identifier: 30510914
author list: Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN
published in: Frontiers in oncology
information resource reference: Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. Front Oncol. 2018; 8:463.
journal title abbreviation: Front Oncol
publication date: 2018-11-19T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
PubMed Identifier: 19259675
author list: Bellmunt J, Calvo E, Castellano D, Climent MA, Esteban E, García del Muro X, González-Larriba JL, Maroto P, Trigo JM
published in: Cancer chemotherapy and pharmacology
information resource reference: Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol. 2009 Mar; 63 Suppl 1:S1-13.
journal title abbreviation: Cancer Chemother Pharmacol
publication date: 2009-03-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

New agents for bladder cancer.
PubMed Identifier: 20943643
author list: Bellmunt J, Guix M
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: New agents for bladder cancer. Ann Oncol. 2010 Oct; 21 Suppl 7:vii56-8.
journal title abbreviation: Ann Oncol
publication date: 2010-10-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Indirect treatment comparison of bevacizumab + interferon-a-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.
PubMed Identifier: 21935329
author list: Mickisch GH, Schwander B, Escudier B, Bellmunt J, Maroto JP, Porta C, Walzer S, Siebert U
published in: ClinicoEconomics and outcomes research : CEOR
information resource reference: Indirect treatment comparison of bevacizumab + interferon-a-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Clinicoecon Outcomes Res. 2011; 3:19-27.
journal title abbreviation: Clinicoecon Outcomes Res
publication date: 2011-01-25T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.
PubMed Identifier: 22674353
author list: González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, Bellmunt J
published in: Cancer metastasis reviews
information resource reference: Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev. 2012 Sep; 31 Suppl 1:S11-7.
journal title abbreviation: Cancer Metastasis Rev
publication date: 2012-09-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1121148
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
PubMed Identifier: 30570744
author list: Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE
published in: Cancer
information resource reference: Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2019 02 15; 125(4):533-540.
journal title abbreviation: Cancer
publication date: 2018-12-20T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1122452
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
PubMed Identifier: 30593515
author list: Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, Choueiri TK, Sonpavde G, Kwiatkowski DJ
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2019 04 15; 25(8):2458-2470.
journal title abbreviation: Clin Cancer Res
publication date: 2018-12-28T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain.
PubMed Identifier: 7865239
author list: Ribas A, Bellmunt J, Albanell J, Capdevila JA, Ocaña I, Gallego OS, Maldonado J, Giralt J, Solé LA
published in: Acta oncologica (Stockholm, Sweden)
information resource reference: Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain. Acta Oncol. 1995; 34(1):75-82.
journal title abbreviation: Acta Oncol
publication date: 1995-01-01T00:00:00
year: 1995
type: Academic Article
type: Article
type: Document
type: Information Resource

Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin.
PubMed Identifier: 9315406
author list: Ribas A, Gallardo E, Vera R, Casado S, Vidal R, Bellmunt J
published in: Clinical oncology (Royal College of Radiologists (Great Britain))
information resource reference: Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin. Clin Oncol (R Coll Radiol). 1997; 9(4):269-70.
journal title abbreviation: Clin Oncol (R Coll Radiol)
publication date: 1997-01-01T00:00:00
year: 1997
type: Academic Article
type: Article
type: Document
type: Information Resource

p53 oncoprotein as a prognostic indicator in patients with breast cancer.
PubMed Identifier: 9580543
author list: Molina R, Segui MA, Climent MA, Bellmunt J, Albanelll J, Fernandez M, Filella X, Jo J, Gimenez N, Iglesias E, Miralles M, Alonso C, Peiro G, Perez-Picañol E, Ballesta AM
published in: Anticancer research
information resource reference: p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res. 1998 Jan-Feb; 18(1B):507-11.
journal title abbreviation: Anticancer Res
publication date: 1998-01-01T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)
PubMed Identifier: 9789610
author list: Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro J, Bellmunt J, Arranz F, Valentí V, Escudero P, Menéndez D, Casado A, Poveda A
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol. 1998 Aug; 9(8):871-6.
journal title abbreviation: Ann Oncol
publication date: 1998-08-01T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

New chemotherapy combinations for advanced bladder cancer.
PubMed Identifier: 11493774
author list: Bellmunt J, Albiol S
published in: Current opinion in urology
information resource reference: New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol. 2001 Sep; 11(5):517-22.
journal title abbreviation: Curr Opin Urol
publication date: 2001-09-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Cavitary pulmonary metastases in transitional cell carcinoma of the urinary bladder.
PubMed Identifier: 1598725
author list: Rovirosa A, Salud A, Felip E, Capdevila F, Giralt J, Bellmunt J
published in: Urologia internationalis
information resource reference: Cavitary pulmonary metastases in transitional cell carcinoma of the urinary bladder. Urol Int. 1992; 48(1):102-4.
journal title abbreviation: Urol Int
publication date: 1992-01-01T00:00:00
year: 1992
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 106902
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.

Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
PubMed Identifier: 17092282
author list: Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A
published in: BJU international
information resource reference: Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int. 2007 Feb; 99(2):274-80.
journal title abbreviation: BJU Int
publication date: 2006-12-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1058
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls.

Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
PubMed Identifier: 19454472
author list: Bellmunt J, Albiol S, Kataja V
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May; 20 Suppl 4:79-80.
journal title abbreviation: Ann Oncol
publication date: 2009-05-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
PubMed Identifier: 21704448
author list: Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J
published in: European urology
information resource reference: ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011 Oct; 60(4):684-90.
journal title abbreviation: Eur Urol
publication date: 2011-06-24T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1127885
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.
PubMed Identifier: 30684034
author list: Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A
published in: World journal of urology
information resource reference: SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019 Jan; 37(1):61-83.
journal title abbreviation: World J Urol
publication date: 2019-01-25T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.
PubMed Identifier: 23322192
author list: Procopio G, Bellmunt J, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B, Hutson TE
published in: British journal of cancer
information resource reference: Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer. 2013 Feb 05; 108(2):311-8.
journal title abbreviation: Br J Cancer
publication date: 2013-01-15T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1139333
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.

The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.
PubMed Identifier: 30851984
author list: Kim J, Kwiatkowski D, McConkey DJ, Meeks JJ, Freeman SS, Bellmunt J, Getz G, Lerner SP
published in: European urology
information resource reference: The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. Eur Urol. 2019 06; 75(6):961-964.
journal title abbreviation: Eur Urol
publication date: 2019-03-07T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Carcinoma, Transitional Cell
MeSH DescriptorUI: D002295
MeSH semantic group name: Disorders
number of authors: 292
number of publications: 824
uniqueness weight: 0.596737
type: Concept

Antineoplastic Combined Chemotherapy Protocols
MeSH DescriptorUI: D000971
MeSH semantic group name: Procedures
number of authors: 1828
number of publications: 12496
uniqueness weight: 0.217379
type: Concept

Authorship 1141806
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.

Authorship 1143396
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Treatment of Metastatic Urothelial Cancer in 2018.

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.
PubMed Identifier: 30936379
author list: Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD
published in: The oncologist
information resource reference: The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist. 2019 10; 24(10):1348-1355.
journal title abbreviation: Oncologist
publication date: 2019-04-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Treatment of Metastatic Urothelial Cancer in 2018.
PubMed Identifier: 30973581
author list: Bellmunt J, Rodriguez-Vida A
published in: JAMA oncology
information resource reference: Treatment of Metastatic Urothelial Cancer in 2018. JAMA Oncol. 2019 Jun 01; 5(6):904-905.
journal title abbreviation: JAMA Oncol
publication date: 2019-06-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1148866
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities.

Authorship 1148826
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.

Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities.
PubMed Identifier: 31015643
author list: Martínez-Bosch N, Rodriguez-Vida A, Juanpere N, Lloreta J, Rovira A, Albanell J, Bellmunt J, Navarro P
published in: Nature reviews. Urology
information resource reference: Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunities. Nat Rev Urol. 2019 07; 16(7):433-445.
journal title abbreviation: Nat Rev Urol
publication date: 2019-07-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.
PubMed Identifier: 31016435
author list: Segalés L, Juanpere N, Lorenzo M, Albero-González R, Fumadó L, Cecchini L, Bellmunt J, Lloreta-Trull J, Hernández-Llodrà S
published in: Virchows Archiv : an international journal of pathology
information resource reference: Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome. Virchows Arch. 2019 Oct; 475(4):457-466.
journal title abbreviation: Virchows Arch
publication date: 2019-04-23T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Urothelium
MeSH DescriptorUI: D019459
MeSH semantic group name: Anatomy
number of authors: 142
number of publications: 285
uniqueness weight: 0.829763
type: Concept

Authorship 1149819
type: Authorship
author rank in publication: 20
linked author: Bellmunt Molins, Joaquin
linked information resource: Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Authorship 1150155
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.

Authorship 1150404
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Management of metastatic bladder cancer.

Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.
PubMed Identifier: 31046476
author list: Darling HS, Bellmunt J
published in: Expert opinion on biological therapy
information resource reference: Immunotherapy in non-metastatic urothelial cancer: back to the 'future'. Expert Opin Biol Ther. 2019 07; 19(7):685-695.
journal title abbreviation: Expert Opin Biol Ther
publication date: 2019-05-02T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Management of metastatic bladder cancer.
PubMed Identifier: 31030123
author list: Nadal R, Bellmunt J
published in: Cancer treatment reviews
information resource reference: Management of metastatic bladder cancer. Cancer Treat Rev. 2019 Jun; 76:10-21.
journal title abbreviation: Cancer Treat Rev
publication date: 2019-04-15T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
PubMed Identifier: 31050707
author list: Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019 06 01; 30(6):970-976.
journal title abbreviation: Ann Oncol
publication date: 2019-06-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Urologic Neoplasms
MeSH DescriptorUI: D014571
MeSH semantic group name: Disorders
number of authors: 142
number of publications: 325
uniqueness weight: 0.739808
type: Concept

Urinary Bladder Neoplasms
MeSH DescriptorUI: D001749
MeSH semantic group name: Disorders
number of authors: 599
number of publications: 2321
uniqueness weight: 0.400367
type: Concept

Medicine
type: Department
type: Organization

Pathology
type: Department
type: Organization

Radiation Oncology
type: Department
type: Organization

Surgery
type: Department
type: Organization

General Medicine
type: Division
type: Organization

Oncology
type: Division
type: Organization

Pulmonary
type: Division
type: Organization

Beth Israel Deaconess Medical Center
type: Organization

Brigham and Women's Hospital
type: Organization

Dana-Farber Cancer Institute
type: Organization

Massachusetts General Hospital
type: Organization

Signoretti, Sabina
eCommons Login: SS49
first name: Sabina
last name: Signoretti
full name: Sabina Signoretti, M.D.
has faculty rank: Full Professor
latitude: 42.33510370000000
longitude: -71.10616490000000
Person ID: 11876
person in primary position: Professor of Pathology
type: Agent
type: Person
preferred title: Professor of Pathology

Authorship 1152278
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.

Authorship 1153587
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.

Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
PubMed Identifier: 31100232
author list: Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, Lipsitz SR, Bellmunt J, Menon M, Choueiri TK, Abdollah F
published in: European urology oncology
information resource reference: Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol. 2018 05; 1(1):83-90.
journal title abbreviation: Eur Urol Oncol
publication date: 2018-05-15T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
PubMed Identifier: 31090082
author list: Hernández-Llodrà S, Segalés L, Safont A, Juanpere N, Lorenzo M, Fumadó L, Rodríguez-Vida A, Cecchini L, Bellmunt J, Lloreta-Trull J
published in: The Prostate
information resource reference: SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer. Prostate. 2019 07; 79(10):1156-1165.
journal title abbreviation: Prostate
publication date: 2019-05-15T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Kwiatkowski, David
eCommons Login: DJK5
first name: David
last name: Kwiatkowski
full name: David Joseph Kwiatkowski, M.D., Ph.D.
has faculty rank: Full Professor
latitude: 42.33812600000000
longitude: -71.10492100000000
Person ID: 56716
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Efstathiou, Jason
eCommons Login: JAE10
first name: Jason
last name: Efstathiou
full name: Jason Alexander Efstathiou, M.D., Ph.D.
has faculty rank: Full Professor
latitude: 42.36389900000000
longitude: -71.06777800000000
Person ID: 79577
person in primary position: Professor of Radiation Oncology
type: Agent
type: Person
preferred title: Professor of Radiation Oncology

Choueiri, Toni
eCommons Login: TKC6
first name: Toni
last name: Choueiri
full name: Toni K. Choueiri, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
photo: https://connects.catalyst.harvard.edu/Profiles/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx
Person ID: 77491
person in primary position: Jerome and Nancy Kohlberg Professor of Medicine
type: Agent
type: Person
preferred title: Jerome and Nancy Kohlberg Professor of Medicine

Authorship 123502
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

Authorship 1158491
type: Authorship
author rank in publication: 13
linked author: Bellmunt Molins, Joaquin
linked information resource: Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Ka Inhibitor TAK-117 in Preclinical Bladder Cancer Models.

Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Ka Inhibitor TAK-117 in Preclinical Bladder Cancer Models.
PubMed Identifier: 31160383
author list: Hernández-Prat A, Rodriguez-Vida A, Juanpere-Rodero N, Arpi O, Menéndez S, Soria-Jiménez L, Martínez A, Iarchouk N, Rojo F, Albanell J, Brake R, Rovira A, Bellmunt J
published in: Molecular cancer research : MCR
information resource reference: Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Ka Inhibitor TAK-117 in Preclinical Bladder Cancer Models. Mol Cancer Res. 2019 09; 17(9):1931-1944.
journal title abbreviation: Mol Cancer Res
publication date: 2019-06-03T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

selected publications
maximum weight: 1
minimum weight: 1
number of connections: 460
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/113
predicate: selected publications
type: Network

research areas
maximum weight: 15.9704
minimum weight: 0.00163827
number of connections: 682
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/217
predicate: research areas
type: Network

coauthor of
maximum weight: 8.60761
minimum weight: 0.0191719
number of connections: 67
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/363
predicate: coauthor of
type: Network

similar to
maximum weight: 919.037
minimum weight: 66.3769
number of connections: 60
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/494
predicate: similar to
type: Network

Van Allen, Eliezer
eCommons Login: EMV7
first name: Eliezer
last name: Van Allen
full name: Eliezer Mendel Van Allen, M.D.
has faculty rank: Full Professor
latitude: 42.33582300000000
longitude: -71.10748200000000
Person ID: 92520
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Authorship 1164035
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
PubMed Identifier: 31200838
author list: Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Théodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A
published in: European urology oncology
information resource reference: Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. Eur Urol Oncol. 2019 05; 2(3):248-256.
journal title abbreviation: Eur Urol Oncol
publication date: 2018-09-07T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1165388
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.

Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019.
PubMed Identifier: 31235192
author list: Grimm MO, Bex A, De Santis M, Ljungberg B, Catto JWF, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M, Van Poppel H
published in: European urology
information resource reference: Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. Eur Urol. 2019 Sep; 76(3):368-380.
journal title abbreviation: Eur Urol
publication date: 2019-06-21T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

McDermott, David
eCommons Login: DFM7
first name: David
last name: McDermott
full name: David Francis McDermott, M.D.
has faculty rank: Full Professor
Person ID: 83685
person in primary position: Victor J. Aresty Professor of Medicine
type: Agent
type: Person
preferred title: Victor J. Aresty Professor of Medicine

Authorship 142776
type: Authorship
author rank in publication: 15
linked author: Bellmunt Molins, Joaquin
linked information resource: Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.

Authorship 148429
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Orbital metastasis, by transitional cell carcinoma of the bladder.

Authorship 149247
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Experience with sorafenib and the elderly patient.

Professor of Radiation Oncology
is primary position: true
position in department: Radiation Oncology
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Professor of Radiation Oncology
position in organization: Massachusetts General Hospital

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Pulmonary
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Brigham and Women's Hospital

Authorship 136724
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

Authorship 178159
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.

Authorship 168829
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Cavitary pulmonary metastases in transitional cell carcinoma of the urinary bladder.

Authorship 170666
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.

Authorship 173876
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.

Authorship 137226
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].

Authorship 221858
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: [Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult].

Authorship 1282400
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.

Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
PubMed Identifier: 32868381
author list: Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodriguez-Vida A, Wankowicz SA, Bowden M, Barletta JA, Morote J, de Torres I, Juanpere N, Lloreta-Trull J, Hernandez S, Mouw KW, Taplin ME, Cejas P, Long HW, Van Allen EM, Getz G, Kwiatkowski DJ
published in: Cancer research
information resource reference: Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Cancer Res. 2020 10 15; 80(20):4476-4486.
journal title abbreviation: Cancer Res
publication date: 2020-08-31T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 187970
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: New perspectives in the therapy of castration resistant prostate cancer.

Authorship 188095
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.

Authorship 156050
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Late recurrent metastasis in Wilms' tumour.

Authorship 134604
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Diagnostic value of bronchoalveolar lavage in peripheral lung cancer.

Authorship 137216
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Maximizing outcomes in genitourinary cancers across the treatment continuum.

Authorship 141738
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1064614

Authorship 199718
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients.

Authorship 1339200
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
PubMed Identifier: 33721560
author list: Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T
published in: The Lancet. Oncology
information resource reference: Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537.
journal title abbreviation: Lancet Oncol
publication date: 2021-03-12T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 161024
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Recommendations for the optimal management of early and advanced urothelial carcinoma.

Authorship 1361130
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's reply.

Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's reply.
PubMed Identifier: 34087147
author list: Bellmunt J
published in: The Lancet. Oncology
information resource reference: Adjuvant immunotherapy in muscle-invasive urothelial carcinoma - Author's reply. Lancet Oncol. 2021 06; 22(6):e238.
journal title abbreviation: Lancet Oncol
publication date: 2021-06-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 183134
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer.

Authorship 156658
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses.

Authorship 156769
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.

Authorship 187771
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1130636

Authorship 215344
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: [New cell target treatments: indications, results and tolerance].

Authorship 158001
type: Authorship
author rank in publication: 14
linked author: Bellmunt Molins, Joaquin
linked information resource: Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.

Instructor in Medicine
is primary position: true
position in department: Medicine
position in division: General Medicine
sort order: 1
type: Position
HR job title: Instructor in Medicine
position in organization: Brigham and Women's Hospital

Authorship 197321
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Indirect treatment comparison of bevacizumab + interferon-a-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.

Authorship 265825
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.

Authorship 344037
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule.

Authorship 426690
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Nail-fold capillary microscopy and chemotherapy-induced vascular toxicity.

Authorship 463079
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [Gene therapy: new prospects in the treatment of cancer].

Authorship 22172
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.

Authorship 171577
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.

Authorship 194984
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: EORTC-GU group expert opinion on metastatic renal cell cancer.

Authorship 206656
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [The incidence of second neoplasms in advanced laryngeal cancer. Impact on survival].

Authorship 263345
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Mitomycin-C and vinblastine in advanced breast cancer.

Oligometastatic Bladder Cancer: Defining a Novel Entity.
PubMed Identifier: 37414704
author list: Labaki C, Saad E, Choueiri TK, Bellmunt J
published in: European urology
information resource reference: Oligometastatic Bladder Cancer: Defining a Novel Entity. Eur Urol. 2023 10; 84(4):390-392.
journal title abbreviation: Eur Urol
publication date: 2023-07-05T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 219526
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Overview of gemcitabine triplets in metastatic bladder cancer.

Authorship 340265
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
PubMed Identifier: 37871703
author list: McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann Oncol. 2024 Jan; 35(1):91-97.
journal title abbreviation: Ann Oncol
publication date: 2023-10-21T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 461619
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.

Authorship 536879
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

Authorship 516742
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

Authorship 524120
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Castration-resistant prostate cancer: new science and therapeutic prospects.

Authorship 529758
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: [Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide].

Authorship 164147
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Prostate cancer. Multidisciplinary approach: a key to success.

Authorship 1662620
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?

Authorship 1660392
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.

Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
PubMed Identifier: 38878766
author list: Bellmunt J, Nadal R
published in: Med (New York, N.Y.)
information resource reference: Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind? Med. 2024 Jun 14; 5(6):490-492.
journal title abbreviation: Med
publication date: 2024-06-14T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.
PubMed Identifier: 38905731
author list: Bellmunt J, Maroto P, Bonfill T, Vazquez F, Perez-Gracia JL, Juanpere N, Hernandez-Prat A, Hernandez-Llodra S, Rovira A, Juan O, Rodriguez-Vida A
published in: Clinical genitourinary cancer
information resource reference: Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. Clin Genitourin Cancer. 2024 Oct; 22(5):102123.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2024-05-23T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 360305
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.

Authorship 361340
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.

Professor of Pathology
is primary position: true
position in department: Pathology
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Professor of Pathology
position in organization: Brigham and Women's Hospital

Assistant Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Assistant Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Jerome and Nancy Kohlberg Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Jerome and Nancy Kohlberg Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 444383
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

Authorship 341426
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: [Epithelioid hemangioendothelioma of the liver].

Authorship 648806
type: Authorship
author rank in publication: 29
linked author: Bellmunt Molins, Joaquin
linked information resource: Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.

Authorship 649884
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Targeted therapies and the treatment of non-clear cell renal cell carcinoma.

Authorship 665750
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.

Authorship 667163
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial.

Authorship 667705
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.

Authorship 644756
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: The treating scenario in genitourinary oncology: what is new? Part 2.

Authorship 646423
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authorship 641212
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Discovery of myopodin methylation in bladder cancer.

Authorship 649267
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/25900766

Authorship 650593
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy.

Authorship 666548
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: A new approach to second-line therapy for urothelial cancer?

Authorship 661991
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.

Authorship 649683
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authorship 656251
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: The treating scenario in genitourinary oncology: what is new? Part 1.

Authorship 650476
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA.

Authorship 640324
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/25902703

Authorship 664625
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.

Discovery of myopodin methylation in bladder cancer.
PubMed Identifier: 18636402
author list: Cebrian V, Alvarez M, Aleman A, Palou J, Bellmunt J, Gonzalez-Peramato P, Cordón-Cardo C, García J, Piulats JM, Sánchez-Carbayo M
published in: The Journal of pathology
information resource reference: Discovery of myopodin methylation in bladder cancer. J Pathol. 2008 Sep; 216(1):111-9.
journal title abbreviation: J Pathol
publication date: 2008-09-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

The treating scenario in genitourinary oncology: what is new? Part 1.
PubMed Identifier: 23718299
author list: Bracarda S, Montironi R, Porta C, Szczylic C, Bearz A, Cartenì G, Bellmunt J
published in: Future oncology (London, England)
information resource reference: The treating scenario in genitourinary oncology: what is new? Part 1. Future Oncol. 2013 Jun; 9(6):797-801.
journal title abbreviation: Future Oncol
publication date: 2013-06-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Perspectives on treatment of metastatic castration-resistant prostate cancer.
PubMed Identifier: 23671006
author list: Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM
published in: The oncologist
information resource reference: Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013; 18(5):558-67.
journal title abbreviation: Oncologist
publication date: 2013-05-13T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

The treating scenario in genitourinary oncology: what is new? Part 2.
PubMed Identifier: 23718300
author list: Bracarda S, Montironi R, Porta C, Szczylic C, Bearz A, Cartenì G, Bellmunt J
published in: Future oncology (London, England)
information resource reference: The treating scenario in genitourinary oncology: what is new? Part 2. Future Oncol. 2013 Jun; 9(6):803-6.
journal title abbreviation: Future Oncol
publication date: 2013-06-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
PubMed Identifier: 23799855
author list: Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J
published in: British journal of cancer
information resource reference: Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. Br J Cancer. 2013 Jul 09; 109(1):121-30.
journal title abbreviation: Br J Cancer
publication date: 2013-06-25T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial.
PubMed Identifier: 23509316
author list: Gallén M, Gallego R, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial. J Clin Oncol. 2013 Apr 20; 31(12):1609.
journal title abbreviation: J Clin Oncol
publication date: 2013-03-18T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/25900766
PubMed Identifier: 23722472
author list: de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J
published in: British journal of cancer
information resource reference: Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br J Cancer. 2013 Jun 25; 108(12):2565-72.
journal title abbreviation: Br J Cancer
publication date: 2013-05-30T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.

https://connects.catalyst.harvard.edu/Profiles/profile/25902703
PubMed Identifier: 23419284
author list: Bellmunt J, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, Culine S, Choueiri TK
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013 Jun; 24(6):1466-72.
journal title abbreviation: Ann Oncol
publication date: 2013-02-17T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.

Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
PubMed Identifier: 23625974
author list: Bellmunt J, Dutcher J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann Oncol. 2013 Jul; 24(7):1730-1740.
journal title abbreviation: Ann Oncol
publication date: 2013-04-26T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Perspectives on treatment of metastatic castration-resistant prostate cancer.
PubMed Identifier: 23814165
author list: Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM
published in: The oncologist
information resource reference: Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013; 18(6):775.
journal title abbreviation: Oncologist
publication date: 2013-01-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.
PubMed Identifier: 23814487
author list: Majumdar S, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, Hager MH, Park PJ, Bellmunt J, Matusik RJ, Rosenberg JE, Adam RM
published in: Neoplasia (New York, N.Y.)
information resource reference: Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia. 2013 Jul; 15(7):749-60.
journal title abbreviation: Neoplasia
publication date: 2013-07-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.
PubMed Identifier: 23559076
author list: Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ
published in: Current urology reports
information resource reference: Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep. 2013 Jun; 14(3):174-83.
journal title abbreviation: Curr Urol Rep
publication date: 2013-06-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

A new approach to second-line therapy for urothelial cancer?
PubMed Identifier: 23706984
author list: Sonpavde G, Galsky MD, Bellmunt J
published in: The Lancet. Oncology
information resource reference: A new approach to second-line therapy for urothelial cancer? Lancet Oncol. 2013 Jul; 14(8):682-4.
journal title abbreviation: Lancet Oncol
publication date: 2013-05-22T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy.
PubMed Identifier: 23851383
author list: Bellmunt J, Pons F, Orsola A
published in: Current opinion in urology
information resource reference: Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Curr Opin Urol. 2013 Sep; 23(5):466-71.
journal title abbreviation: Curr Opin Urol
publication date: 2013-09-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA.
PubMed Identifier: 23914742
author list: López V, González-Peramato P, Suela J, Serrano A, Algaba F, Cigudosa JC, Vidal A, Bellmunt J, Heredero O, Sánchez-Carbayo M
published in: Journal of translational medicine
information resource reference: Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. J Transl Med. 2013 Aug 01; 11:182.
journal title abbreviation: J Transl Med
publication date: 2013-08-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.
PubMed Identifier: 23510293
author list: Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernández Pastor LJ, Bellmunt J
published in: Expert opinion on drug safety
information resource reference: Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain. Expert Opin Drug Saf. 2013 Jul; 12(4):455-63.
journal title abbreviation: Expert Opin Drug Saf
publication date: 2013-03-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
PubMed Identifier: 23317774
author list: Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, Bellmunt J, Choueiri TK
published in: Critical reviews in oncology/hematology
information resource reference: Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013 Jul; 87(1):80-9.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2013-01-12T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 501985
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: European early phase II dose-finding study of droloxifene in advanced breast cancer.

Authorship 51072
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.

Authorship 535275
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [Advanced bladder cancer: new therapeutic strategies].

Authorship 201065
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

Authorship 91831
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: [Peripheral cholangiocarcinoma: results of surgical treatment].

Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.
PubMed Identifier: 24018020
author list: Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J
published in: European urology
information resource reference: Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014 Jul; 66(1):42-54.
journal title abbreviation: Eur Urol
publication date: 2013-08-28T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 675201
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authorship 673533
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: A multinational phase II trial of bevacizumab with low-dose interferon-a2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.

Authorship 677956
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Combination therapy in metastatic renal cell cancer.

Authorship 675886
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.

Authorship 676855
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Molecular targets on the horizon for kidney and urothelial cancer.

Perspectives on treatment of metastatic castration-resistant prostate cancer.
PubMed Identifier: 23986340
author list: Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM
published in: The oncologist
information resource reference: Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013; 18(8):971.
journal title abbreviation: Oncologist
publication date: 2013-01-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Combination therapy in metastatic renal cell cancer.
PubMed Identifier: 23972711
author list: Ravaud A, Gross-Goupil M, Bellmunt J
published in: Seminars in oncology
information resource reference: Combination therapy in metastatic renal cell cancer. Semin Oncol. 2013 Aug; 40(4):472-81.
journal title abbreviation: Semin Oncol
publication date: 2013-08-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
PubMed Identifier: 23788753
author list: Garcia-Donas J, Leandro-García LJ, González Del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, Bellmunt J, Mellado B, Puente J, Moreno F, Font A, Hernando S, Robledo M, Rodríguez-Antona C
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013 Sep; 24(9):2409-14.
journal title abbreviation: Ann Oncol
publication date: 2013-06-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular targets on the horizon for kidney and urothelial cancer.
PubMed Identifier: 23982523
author list: Bellmunt J, Teh BT, Tortora G, Rosenberg JE
published in: Nature reviews. Clinical oncology
information resource reference: Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol. 2013 Oct; 10(10):557-70.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2013-08-27T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

A multinational phase II trial of bevacizumab with low-dose interferon-a2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
PubMed Identifier: 23803225
author list: Melichar B, Bracarda S, Matveev V, Alekseev B, Ivanov S, Zyryanov A, Janciauskiene R, Fernebro E, Mulders P, Osborne S, Jethwa S, Mickisch G, Gore M, van Moorselaar RJ, Staehler M, Magne N, Bellmunt J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: A multinational phase II trial of bevacizumab with low-dose interferon-a2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol. 2013 Sep; 24(9):2396-402.
journal title abbreviation: Ann Oncol
publication date: 2013-06-26T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 15593
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.

Authorship 270135
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain.

Authorship 681799
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.

Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
PubMed Identifier: 23867574
author list: Gallardo E, Arranz JÁ, Maroto JP, León LÁ, Bellmunt J
published in: Critical reviews in oncology/hematology
information resource reference: Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. Crit Rev Oncol Hematol. 2013 Nov; 88(2):357-67.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2013-07-16T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 256240
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Authorship 319330
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Experience with sorafenib and adverse event management.

Authorship 693040
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.

Authorship 692930
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.

Authorship 692955
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.

Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.
PubMed Identifier: 23219086
author list: Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ
published in: European urology
information resource reference: Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol. 2013 Dec; 64(6):994-1002.
journal title abbreviation: Eur Urol
publication date: 2012-11-21T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
PubMed Identifier: 24222142
author list: Paglino C, Procopio G, Sabbatini R, Bellmunt J, Schmidinger M, Bearz A, Bamias A, Melichar B, Imarisio I, Tinelli C, Porta C
published in: Anticancer research
information resource reference: A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. Anticancer Res. 2013 Nov; 33(11):4999-5004.
journal title abbreviation: Anticancer Res
publication date: 2013-11-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.
PubMed Identifier: 24129239
author list: Harshman LC, Fougeray R, Choueiri TK, Schutz FA, Salhi Y, Rosenberg JE, Bellmunt J
published in: British journal of cancer
information resource reference: The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. Br J Cancer. 2013 Nov 12; 109(10):2548-53.
journal title abbreviation: Br J Cancer
publication date: 2013-10-15T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 693385
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.

Authorship 694158
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).

Authorship 694037
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
PubMed Identifier: 24247547
author list: Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS
published in: International journal of oncology
information resource reference: Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol. 2014 Jan; 44(1):5-16.
journal title abbreviation: Int J Oncol
publication date: 2013-11-15T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
PubMed Identifier: 24080920
author list: Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, Bellmunt J, Peters F, Le-Guennec S, Cerbone L, Risse ML, Machiels JP
published in: Oncology
information resource reference: Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology. 2013; 85(4):208-15.
journal title abbreviation: Oncology
publication date: 2013-09-24T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
PubMed Identifier: 23800847
author list: Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G
published in: Clinical genitourinary cancer
information resource reference: Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer. 2013 Dec; 11(4):495-500.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2013-06-22T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 694598
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

Authorship 225239
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1105848

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
PubMed Identifier: 24211163
author list: Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ
published in: The Lancet. Oncology
information resource reference: Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1307-16.
journal title abbreviation: Lancet Oncol
publication date: 2013-11-08T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 695490
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

Authorship 695677
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Sunitinib malate in the treatment of urothelial cancer.

Sunitinib malate in the treatment of urothelial cancer.
PubMed Identifier: 24188025
author list: Pons F, Bellmunt J
published in: Expert opinion on investigational drugs
information resource reference: Sunitinib malate in the treatment of urothelial cancer. Expert Opin Investig Drugs. 2014 Jan; 23(1):115-24.
journal title abbreviation: Expert Opin Investig Drugs
publication date: 2013-11-04T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
PubMed Identifier: 24207135
author list: Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N
published in: European urology
information resource reference: EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014 Jan; 65(1):124-37.
journal title abbreviation: Eur Urol
publication date: 2013-10-06T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 168471
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.

Authorship 699373
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: The evolving understanding of microRNA in bladder cancer.

The evolving understanding of microRNA in bladder cancer.
PubMed Identifier: 23911686
author list: Guancial EA, Bellmunt J, Yeh S, Rosenberg JE, Berman DM
published in: Urologic oncology
information resource reference: The evolving understanding of microRNA in bladder cancer. Urol Oncol. 2014 Jan; 32(1):41.e31-40.
journal title abbreviation: Urol Oncol
publication date: 2013-08-02T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 701418
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
PubMed Identifier: 24321502
author list: Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N
published in: European urology
information resource reference: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014 Feb; 65(2):467-79.
journal title abbreviation: Eur Urol
publication date: 2013-11-12T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Hyponatremia associated with worse outcomes in metastatic renal cell cancer: a potential target for intervention?
PubMed Identifier: 24262101
author list: Bellmunt J, Leow JJ
published in: European urology
information resource reference: Hyponatremia associated with worse outcomes in metastatic renal cell cancer: a potential target for intervention? Eur Urol. 2014 Apr; 65(4):731-2.
journal title abbreviation: Eur Urol
publication date: 2013-11-11T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 256484
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.

Authorship 246380
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.

Authorship 397156
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Epithelioid hemangioendothelioma of the liver with myocardial metastases.

Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.
PubMed Identifier: 24486590
author list: Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83.
journal title abbreviation: Clin Cancer Res
publication date: 2014-01-31T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 297458
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Toxicities of targeted therapy and their management in kidney cancer.

Reply from authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2014;66:55-6.
PubMed Identifier: 24568895
author list: Leow JJ, Chang SL, Bellmunt J
published in: European urology
information resource reference: Reply from authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2014;66:55-6. Eur Urol. 2014 Jul; 66(1):57-8.
journal title abbreviation: Eur Urol
publication date: 2014-02-14T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis.
PubMed Identifier: 24674655
author list: Leow JJ, Reese S, Trinh QD, Bellmunt J, Chung BI, Kibel AS, Chang SL
published in: BJU international
information resource reference: Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int. 2015 May; 115(5):713-21.
journal title abbreviation: BJU Int
publication date: 2015-01-26T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States.
PubMed Identifier: 24491306
author list: Leow JJ, Reese SW, Jiang W, Lipsitz SR, Bellmunt J, Trinh QD, Chung BI, Kibel AS, Chang SL
published in: European urology
information resource reference: Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014 Sep; 66(3):569-76.
journal title abbreviation: Eur Urol
publication date: 2014-01-28T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.
PubMed Identifier: 24680361
author list: Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J
published in: European urology
information resource reference: A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. 2014 Sep; 66(3):529-41.
journal title abbreviation: Eur Urol
publication date: 2014-03-16T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Associate Professor of Surgery
is primary position: true
position in department: Surgery
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Associate Professor of Surgery
position in organization: Brigham and Women's Hospital

Authorship 714296
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: New treatments for bladder cancer: when will we make progress?

Authorship 725090
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: In reply.

Authorship 722282
type: Authorship
author rank in publication: 16
linked author: Bellmunt Molins, Joaquin
linked information resource: Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.

Authorship 724268
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

Authorship 715248
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

Authorship 721361
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Hyponatremia associated with worse outcomes in metastatic renal cell cancer: a potential target for intervention?

Authorship 723659
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

Authorship 712178
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial.

Authorship 722964
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.

Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
PubMed Identifier: 24220220
author list: Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G
published in: Clinical genitourinary cancer
information resource reference: Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):130-7.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2013-09-28T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
PubMed Identifier: 24475095
author list: Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suarez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martínez E, Moreno F, Font A, Calvo A
published in: PloS one
information resource reference: Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One. 2014; 9(1):e86263.
journal title abbreviation: PLoS One
publication date: 2014-01-24T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
PubMed Identifier: 24297945
author list: Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014 Mar 10; 32(8):752-9.
journal title abbreviation: J Clin Oncol
publication date: 2013-12-02T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

In reply.
PubMed Identifier: 24536028
author list: Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM
published in: The oncologist
information resource reference: In reply. Oncologist. 2014 Mar; 19(3):305-6.
journal title abbreviation: Oncologist
publication date: 2014-02-17T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

New treatments for bladder cancer: when will we make progress?
PubMed Identifier: 24415439
author list: Nadal R, Bellmunt J
published in: Current treatment options in oncology
information resource reference: New treatments for bladder cancer: when will we make progress? Curr Treat Options Oncol. 2014 Mar; 15(1):99-114.
journal title abbreviation: Curr Treat Options Oncol
publication date: 2014-03-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial.
PubMed Identifier: 24559444
author list: Nadal R, Taplin ME, Bellmunt J
published in: Future oncology (London, England)
information resource reference: Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncol. 2014 Feb; 10(3):351-62.
journal title abbreviation: Future Oncol
publication date: 2014-02-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.
PubMed Identifier: 24570330
author list: Castellano DE, Bellmunt J, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suarez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J
published in: Cancer chemotherapy and pharmacology
information resource reference: Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemother Pharmacol. 2014 Apr; 73(4):857-67.
journal title abbreviation: Cancer Chemother Pharmacol
publication date: 2014-02-26T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 232580
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma.

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 268739
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: The medical management of prostate cancer: a multidisciplinary team approach.

Victor J. Aresty Professor of Medicine
is primary position: true
position in department: Medicine
position in division: DF Melanoma
sort order: 1
type: Position
HR job title: Victor J. Aresty Professor of Medicine
position in organization: Beth Israel Deaconess Medical Center

DF Melanoma
type: Division
type: Organization

Authorship 727477
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.

Authorship 728475
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
PubMed Identifier: 24219029
author list: Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G
published in: BJU international
information resource reference: A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43.
journal title abbreviation: BJU Int
publication date: 2014-05-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.
PubMed Identifier: 24594299
author list: Calvo E, Grünwald V, Bellmunt J
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. Eur J Cancer. 2014 May; 50(7):1321-9.
journal title abbreviation: Eur J Cancer
publication date: 2014-03-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1784173
type: Authorship
author rank in publication: 14
linked author: Bellmunt Molins, Joaquin
linked information resource: The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.

Authorship 1774087
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Oligometastatic Bladder Cancer: Defining a Novel Entity.

Authorship 271419
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/857241

Martin-Doyle, William
eCommons Login: WM51
first name: William
last name: Martin-Doyle
full name: William Martin-Doyle, M.D.
has faculty rank: Instructor
Person ID: 106836
person in primary position: Instructor in Medicine
type: Agent
type: Person
preferred title: Instructor in Medicine

Authorship 735613
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Reply from authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2014;66:55-6.

Authorship 736328
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
PubMed Identifier: 24821883
author list: Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
journal title abbreviation: J Clin Oncol
publication date: 2014-05-12T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Adrenocortical carcinoma: the management of metastatic disease.
PubMed Identifier: 24958272
author list: Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, Choueiri TK
published in: Critical reviews in oncology/hematology
information resource reference: Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014 Nov; 92(2):123-32.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2014-06-04T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1788697
type: Authorship
author rank in publication: 19
linked author: Bellmunt Molins, Joaquin
linked information resource: Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.

Authorship 1791980
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Progress in systemic therapy for advanced-stage urothelial carcinoma.

Authorship 1822577
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.

Authorship 1843252
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.

Authorship 1841636
type: Authorship
author rank in publication: 19
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/323011950

Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.
PubMed Identifier: 39979258
author list: Boll LM, Vázquez Montes de Oca S, Camarena ME, Castelo R, Bellmunt J, Perera-Bel J, Albà MM
published in: Nature communications
information resource reference: Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts. Nat Commun. 2025 Feb 20; 16(1):1213.
journal title abbreviation: Nat Commun
publication date: 2025-02-20T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
PubMed Identifier: 40467365
author list: Bellmunt J, Powles T, Park SH, Voog E, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Sternberg CN, Aragon-Ching JB, Petrylak DP, Climent Duran MA, Tyroller K, Hoffman J, Jacob N, Grivas P, Gupta S
published in: European urology
information resource reference: Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease. Eur Urol. 2025 Oct; 88(4):331-338.
journal title abbreviation: Eur Urol
publication date: 2025-06-03T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Progress in systemic therapy for advanced-stage urothelial carcinoma.
PubMed Identifier: 37945764
author list: Nadal R, Valderrama BP, Bellmunt J
published in: Nature reviews. Clinical oncology
information resource reference: Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat Rev Clin Oncol. 2024 Jan; 21(1):8-27.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2023-11-09T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/323011950
PubMed Identifier: 39214051
author list: Rodriguez-Vida A, Valderrama BP, Castellano D, Pinto A, Mellado B, Puente J, Climent MA, Domenech M, Vazquez F, Perez-Gracia JL, Bonfill T, Morales-Barrera R, Gonzalez-Billalabeitia E, Garcia-Del-Muro X, Maroto P, Navarro-Gorro N, Juanpere N, Juan O, Bellmunt J
published in: ESMO open
information resource reference: Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024 Sep; 9(9):103690.
journal title abbreviation: ESMO Open
publication date: 2024-08-29T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.

Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
PubMed Identifier: 36289372
author list: Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J
published in: British journal of cancer
information resource reference: Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. Br J Cancer. 2023 01; 128(1):21-29.
journal title abbreviation: Br J Cancer
publication date: 2022-10-26T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 737769
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
PubMed Identifier: 24703899
author list: Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014 Jun; 50(9):1617-27.
journal title abbreviation: Eur J Cancer
publication date: 2014-04-03T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 434592
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.

Authorship 292062
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.

Authorship 299791
type: Authorship
author rank in publication: 14
linked author: Bellmunt Molins, Joaquin
linked information resource: ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.

Authorship 458700
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Interferon and disseminated Langerhans cell histiocytosis.

Authorship 461434
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.

Authorship 361354
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authorship 398807
type: Authorship
author rank in publication: 20
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.

Authorship 496171
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authorship 747884
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.

Authorship 751407
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.

Authorship 750447
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Unveiling the surgical risk associated with neoadjuvant chemotherapy in bladder cancer.

Authorship 751933
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.

Authorship 751455
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Identification of ALK gene alterations in urothelial carcinoma.

Unveiling the surgical risk associated with neoadjuvant chemotherapy in bladder cancer.
PubMed Identifier: 25070136
author list: Bellmunt J, Leow JJ, Martin-Doyle W
published in: BJU international
information resource reference: Unveiling the surgical risk associated with neoadjuvant chemotherapy in bladder cancer. BJU Int. 2014 Aug; 114(2):163-4.
journal title abbreviation: BJU Int
publication date: 2014-08-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of ALK gene alterations in urothelial carcinoma.
PubMed Identifier: 25083769
author list: Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE
published in: PloS one
information resource reference: Identification of ALK gene alterations in urothelial carcinoma. PLoS One. 2014; 9(8):e103325.
journal title abbreviation: PLoS One
publication date: 2014-08-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
PubMed Identifier: 24846059
author list: Guancial EA, Werner L, Bellmunt J, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE
published in: Cancer medicine
information resource reference: FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 Aug; 3(4):835-44.
journal title abbreviation: Cancer Med
publication date: 2014-05-21T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
PubMed Identifier: 24795159
author list: Bellmunt J, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK
published in: Clinical genitourinary cancer
information resource reference: Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clin Genitourin Cancer. 2014 Aug; 12(4):262-9.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2014-03-14T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 754189
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
PubMed Identifier: 25142843
author list: Bellmunt J, Suarez C, Gallardo E, Rodon J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J
published in: The oncologist
information resource reference: Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist. 2014 Sep; 19(9):917-8.
journal title abbreviation: Oncologist
publication date: 2014-08-20T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 546234
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents.

Authorship 756309
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.

Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.
PubMed Identifier: 25096609
author list: Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep; 25 Suppl 3:iii40-8.
journal title abbreviation: Ann Oncol
publication date: 2014-08-05T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 574148
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations.

Authorship 763009
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: New agents for prostate cancer.

New agents for prostate cancer.
PubMed Identifier: 24658665
author list: Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: New agents for prostate cancer. Ann Oncol. 2014 Sep; 25(9):1700-1709.
journal title abbreviation: Ann Oncol
publication date: 2014-03-20T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 763449
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States.

Authorship 765163
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: PD-L1 expression in nonclear-cell renal cell carcinoma.

PD-L1 expression in nonclear-cell renal cell carcinoma.
PubMed Identifier: 25193987
author list: Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2178-2184.
journal title abbreviation: Ann Oncol
publication date: 2014-09-05T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 74338
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.

Authorship 92975
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

Authorship 419806
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.

Authorship 460531
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.

Authorship 232371
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.

Authorship 770457
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: SEOM clinical guidelines for the treatment of renal cell carcinoma.

SEOM clinical guidelines for the treatment of renal cell carcinoma.
PubMed Identifier: 25274276
author list: Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I
published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
information resource reference: SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol. 2014 Dec; 16(12):1043-50.
journal title abbreviation: Clin Transl Oncol
publication date: 2014-10-02T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 370810
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: New drugs and new approaches in metastatic bladder cancer.

Authorship 771642
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
PubMed Identifier: 25428503
author list: Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ
published in: Nature
information resource reference: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27; 515(7528):558-62.
journal title abbreviation: Nature
publication date: 2014-11-27T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 438640
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.

Authorship 772552
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.

Authorship 774063
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer.

Authorship 774212
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.

Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.
PubMed Identifier: 25035282
author list: Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR
published in: Clinical genitourinary cancer
information resource reference: Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec; 12(6):395-8.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2014-06-10T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer.
PubMed Identifier: 25108578
author list: Orsola A, Bellmunt J
published in: European urology
information resource reference: The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):30-32.
journal title abbreviation: Eur Urol
publication date: 2014-08-06T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 776103
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.

Authorship 775578
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Enzalutamide in European and North American men participating in the AFFIRM trial.

Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.
PubMed Identifier: 25385730
author list: Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, Choueiri TK
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. J Clin Oncol. 2014 Dec 20; 32(36):4171-2.
journal title abbreviation: J Clin Oncol
publication date: 2014-11-10T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Enzalutamide in European and North American men participating in the AFFIRM trial.
PubMed Identifier: 25123978
author list: Merseburger AS, Scher HI, Bellmunt J, Miller K, Mulders PF, Stenzl A, Sternberg CN, Fizazi K, Hirmand M, Franks B, Haas GP, de Bono J, de Wit R
published in: BJU international
information resource reference: Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int. 2015 Jan; 115(1):41-9.
journal title abbreviation: BJU Int
publication date: 2014-10-23T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 778878
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/36809859

Authorship 778021
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.

Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
PubMed Identifier: 24993933
author list: Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G
published in: Clinical genitourinary cancer
information resource reference: Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015 Feb; 13(1):71-9.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2014-06-09T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/36809859
PubMed Identifier: 25045157
author list: Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS
published in: Cancer medicine
information resource reference: Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med. 2014 Dec; 3(6):1517-26.
journal title abbreviation: Cancer Med
publication date: 2014-07-18T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

Authorship 500225
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells.

Authorship 537771
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

Authorship 283957
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: New agents for bladder cancer.

Authorship 315222
type: Authorship
author rank in publication: 15
linked author: Bellmunt Molins, Joaquin
linked information resource: p53 oncoprotein as a prognostic indicator in patients with breast cancer.

Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.
PubMed Identifier: 25535728
author list: Orsola A, Werner L, de Torres I, Martin-Doyle W, Raventos CX, Lozano F, Mullane SA, Leow JJ, Barletta JA, Bellmunt J, Morote J
published in: British journal of cancer
information resource reference: Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br J Cancer. 2015 Feb 03; 112(3):468-74.
journal title abbreviation: Br J Cancer
publication date: 2014-12-23T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients.
PubMed Identifier: 25559810
author list: Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol. 2015 Feb 20; 33(6):643-50.
journal title abbreviation: J Clin Oncol
publication date: 2015-01-05T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 87118
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: [Pulmonary metastasising benign leiomyoma evolving to chronic respiratory failure].

Authorship 63618
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.

A contemporary review of management and prognostic factors of upper tract urothelial carcinoma.
PubMed Identifier: 25736461
author list: Leow JJ, Orsola A, Chang SL, Bellmunt J
published in: Cancer treatment reviews
information resource reference: A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015 Apr; 41(4):310-9.
journal title abbreviation: Cancer Treat Rev
publication date: 2015-02-18T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 492236
type: Authorship
author rank in publication: 23
linked author: Bellmunt Molins, Joaquin
linked information resource: Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

Authorship 357625
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.

Authorship 231767
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Orbital metastases from transitional-cell cancer of the urinary bladder.

Authorship 47347
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Authorship 184499
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].

Authorship 496761
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.

Authorship 574466
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Sorafenib TARGET trial results in Spanish patients.

Authorship 511835
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Addison's disease secondary to prostatic carcinoma. A case report.

Authorship 62988
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [Regulatory proteins of the cell cycle: alterations in the cycline D1 pathway as a paradigm. Findings in breast cancer].

Authorship 63323
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: [Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases].

Authorship 64787
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

Authorship 181004
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: New therapeutic challenges in advanced bladder cancer.

Authorship 74974
type: Authorship
author rank in publication: 15
linked author: Bellmunt Molins, Joaquin
linked information resource: Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

Authorship 248092
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.

Authorship 198747
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Intermittent chemotherapy in metastatic androgen-independent prostate cancer.

Authorship 312945
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

Authorship 201473
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Authorship 250739
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI).

Authorship 30650
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.

Authorship 210451
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [The clinical importance of the fibroblast growth factor (bFGF) as a biological marker and therapeutic modulator. Future applications].

Authorship 42385
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: [Metachronic squamous carcinoma of the tonsils to microcytic carcinoma of the esophagus].

Authorship 265235
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Advances in the management of high-risk localised and metastatic prostate cancer.

Authorship 209098
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/934013

Authorship 359763
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: [Solitary cerebellar metastases: a clinical neuro-radiological study].

Authorship 340028
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Authorship 459198
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Future developments in renal cell carcinoma.

Authorship 279617
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: [Antineoplastic chemotherapy in digestive tumors].

Authorship 74178
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [Glycoprotein P and resistance to antitumor chemotherapy].

Authorship 279962
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: [Spinal cord compression as a primary manifestation of occult thyroid carcinoma].

Authorship 311638
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

Authorship 28615
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.

Authorship 290905
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1077550

Authorship 293209
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.

Authorship 331148
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.

Authorship 411364
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.

Authorship 157810
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.

Authorship 278129
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Statins and the effect of BCG on bladder cancer.

Authorship 363946
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: The optimize project: beyond first-line therapy in metastatic renal cell carcinoma.

Authorship 347066
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma.

Authorship 357543
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/935490

Authorship 385661
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.

Authorship 411322
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

Authorship 446339
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)

Authorship 487825
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce.

Authorship 507119
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival.

Authorship 51613
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [Current strategies in the treatment of renal-cell cancer: targeted therapies].

Authorship 531115
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal.

Authorship 572660
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Variant forms of bladder cancer: basic considerations on treatment approaches.

Authorship 795240
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.

Authorship 792218
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT).

Authorship 802267
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.

Authorship 803612
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Perioperative therapy for muscle invasive bladder cancer.

Authorship 796303
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis.

Authorship 790755
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.

Authorship 790404
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Adrenocortical carcinoma: the management of metastatic disease.

Authorship 794644
type: Authorship
author rank in publication: 14
linked author: Bellmunt Molins, Joaquin
linked information resource: Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.

Authorship 788976
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.

Authorship 796736
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Bladder cancer.

Authorship 791319
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Incidental focal uptake in colorectal location on oncologic ¹8FDG PET and PET/CT studies: histopathological findings and clinical significances.

Authorship 803790
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/56076253

Authorship 806752
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.

Authorship 796686
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Future directions and targeted therapies in bladder cancer.

Authorship 797723
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.

Authorship 799722
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?

Authorship 791583
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients.

Authorship 794156
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma.

Authorship 792996
type: Authorship
author rank in publication: 20
linked author: Bellmunt Molins, Joaquin
linked information resource: Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

Authorship 801188
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.

Authorship 804416
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Authorship 804758
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Current role of cabozantinib in metastatic castration-resistant prostate cancer.

Authorship 805284
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: A contemporary review of management and prognostic factors of upper tract urothelial carcinoma.

Authorship 805867
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.

Authorship 804102
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona.

Authorship 804258
type: Authorship
author rank in publication: 14
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/56078164

Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
PubMed Identifier: 25018037
author list: Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS
published in: European urology
information resource reference: Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. 2015 May; 67(5):866-73.
journal title abbreviation: Eur Urol
publication date: 2014-07-10T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
PubMed Identifier: 25458370
author list: Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J
published in: Clinical genitourinary cancer
information resource reference: Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015 Apr; 13(2):185-92.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2014-10-02T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
PubMed Identifier: 25623215
author list: Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res. 2015 May 01; 21(9):2157-66.
journal title abbreviation: Clin Cancer Res
publication date: 2015-01-26T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Bladder cancer.
PubMed Identifier: 25836942
author list: Bellmunt J
published in: Hematology/oncology clinics of North America
information resource reference: Bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):xiii-xiv.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2015-01-09T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
PubMed Identifier: 26039708
author list: Bellmunt J, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, Van Hummelen P, Taplin ME, Choueiri TK, Van Allen E, Rosenberg J
published in: PloS one
information resource reference: Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS One. 2015; 10(6):e0124711.
journal title abbreviation: PLoS One
publication date: 2015-06-03T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?
PubMed Identifier: 25845991
author list: Sonpavde G, Bellmunt J
published in: The oncologist
information resource reference: Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change? Oncologist. 2015 May; 20(5):461-3.
journal title abbreviation: Oncologist
publication date: 2015-04-06T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.
PubMed Identifier: 25450035
author list: Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G
published in: Clinical genitourinary cancer
information resource reference: Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer. 2015 Apr; 13(2):178-84.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2014-09-23T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
PubMed Identifier: 25600565
author list: Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, Choueiri TK, Hodi FS, Freeman GJ, Signoretti S
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr; 26(4):812-817.
journal title abbreviation: Ann Oncol
publication date: 2015-01-18T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Current role of cabozantinib in metastatic castration-resistant prostate cancer.
PubMed Identifier: 25586337
author list: Fay AP, Albiges L, Bellmunt J
published in: Expert review of anticancer therapy
information resource reference: Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015 Feb; 15(2):151-6.
journal title abbreviation: Expert Rev Anticancer Ther
publication date: 2015-01-14T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.
PubMed Identifier: 25886454
author list: Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE
published in: BMC cancer
information resource reference: DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 09; 15:242.
journal title abbreviation: BMC Cancer
publication date: 2015-04-09T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/56076253
PubMed Identifier: 25743937
author list: Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K
published in: The Lancet. Oncology
information resource reference: Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015 Apr; 16(4):417-25.
journal title abbreviation: Lancet Oncol
publication date: 2015-03-03T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.
PubMed Identifier: 25767716
author list: Fay AP, Signoretti S, Callea M, Tel? GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK
published in: Journal for immunotherapy of cancer
information resource reference: Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3.
journal title abbreviation: J Immunother Cancer
publication date: 2015-02-17T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Future directions and targeted therapies in bladder cancer.
PubMed Identifier: 25836940
author list: Sonpavde G, Jones BS, Bellmunt J, Choueiri TK, Sternberg CN
published in: Hematology/oncology clinics of North America
information resource reference: Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):361-76, x.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2014-12-13T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/56078164
PubMed Identifier: 25624429
author list: Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 01; 33(7):723-31.
journal title abbreviation: J Clin Oncol
publication date: 2015-01-26T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.

Perioperative therapy for muscle invasive bladder cancer.
PubMed Identifier: 25836936
author list: Leow JJ, Fay AP, Mullane SA, Bellmunt J
published in: Hematology/oncology clinics of North America
information resource reference: Perioperative therapy for muscle invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):301-18, ix.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2015-04-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Incidental focal uptake in colorectal location on oncologic ¹8FDG PET and PET/CT studies: histopathological findings and clinical significances.
PubMed Identifier: 25263718
author list: Fuertes J, Montagut C, Bullich S, Coma MI, Mestre-Fusco A, Suárez-Piñera M, Trampal C, Bellmunt J
published in: Revista espanola de medicina nuclear e imagen molecular
information resource reference: Incidental focal uptake in colorectal location on oncologic ¹8FDG PET and PET/CT studies: histopathological findings and clinical significances. Rev Esp Med Nucl Imagen Mol. 2015 Mar-Apr; 34(2):95-101.
journal title abbreviation: Rev Esp Med Nucl Imagen Mol
publication date: 2014-09-26T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.
PubMed Identifier: 25218582
author list: Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, de Wit R, Gillessen S, Gschwend JE, Hamdy F, James N, McDermott R, Miller K, Wiegel T, Wirth M, Tombal B
published in: European urology
information resource reference: Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol. 2015 May; 67(5):904-12.
journal title abbreviation: Eur Urol
publication date: 2014-09-11T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.
PubMed Identifier: 25481485
author list: Sonpavde G, Pond GR, Mullane S, Qu AQ, Di Lorenzo G, Federico P, Necchi A, Rosenberg JE, Bellmunt J, Choueiri TK
published in: Clinical genitourinary cancer
information resource reference: Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clin Genitourin Cancer. 2015 Jun; 13(3):250-6.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2014-11-07T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT).
PubMed Identifier: 25442842
author list: Gore ME, Bellmunt J, Eisen T, Escudier B, Mickisch G, Patard J, Porta C, Ravaud A, Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, Lewis S, Kirpekar S
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT). Eur J Cancer. 2014 Dec; 50(18):3153-60.
journal title abbreviation: Eur J Cancer
publication date: 2014-10-23T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma.
PubMed Identifier: 25195625
author list: Sonpavde G, Pond GR, Fougeray R, Bellmunt J
published in: BJU international
information resource reference: Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. BJU Int. 2015 Jun; 115(6):854-5.
journal title abbreviation: BJU Int
publication date: 2015-01-21T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona.
PubMed Identifier: 25075878
author list: Murta-Nascimento C, Romero AI, Sala M, Lorente JA, Bellmunt J, Rodero NJ, Lloreta J, Hospital À, Burón A, Castells X, Macià F
published in: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
information resource reference: The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona. Eur J Cancer Prev. 2015 Jul; 24(4):335-9.
journal title abbreviation: Eur J Cancer Prev
publication date: 2015-07-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 17138
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.

Authorship 274277
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: ¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy.

Authorship 291121
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authorship 302658
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: What are the expected developments in the medical treatment of bladder cancer.

Authorship 306886
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/965173

Authorship 405140
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.

Authorship 416129
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Sunitinib in renal-cell carcinoma: expanded indications.

Authorship 39726
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [Primary non-Hodgkin's lymphoma of the breast].

Authorship 556637
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authorship 57246
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.

Authorship 356965
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin.

Authorship 328020
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authorship 817603
type: Authorship
author rank in publication: 15
linked author: Bellmunt Molins, Joaquin
linked information resource: Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
PubMed Identifier: 25872978
author list: Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE
published in: Cancer
information resource reference: Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug 01; 121(15):2586-93.
journal title abbreviation: Cancer
publication date: 2015-04-14T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 41088
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Authorship 824117
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: HER2 as a target in invasive urothelial carcinoma.

HER2 as a target in invasive urothelial carcinoma.
PubMed Identifier: 25720673
author list: Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J
published in: Cancer medicine
information resource reference: HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015 Jun; 4(6):844-52.
journal title abbreviation: Cancer Med
publication date: 2015-02-26T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 45494
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/954825

Authorship 825544
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Reply to K. Lu.

Reply to K. Lu.
PubMed Identifier: 26195703
author list: Martin-Doyle W, Orsola A, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Reply to K. Lu. J Clin Oncol. 2015 Aug 20; 33(24):2716-7.
journal title abbreviation: J Clin Oncol
publication date: 2015-07-20T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010.
PubMed Identifier: 26320810
author list: Cole AP, Dalela D, Hanske J, Mullane SA, Choueiri TK, Meyer CP, Nguyen PL, Menon M, Kibel AS, Preston MA, Bellmunt J, Trinh QD
published in: Urologic oncology
information resource reference: Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Dec; 33(12):504.e9-17.
journal title abbreviation: Urol Oncol
publication date: 2015-08-25T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 53806
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [Corticoid treatment in Castleman's disease].

Authorship 835988
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: New advances in genitourinary cancer: evidence gathered in 2014.

Authorship 833971
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?

Authorship 835262
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Precision and predictive medicine in urothelial cancer: are we making progress?

Precision and predictive medicine in urothelial cancer: are we making progress?
PubMed Identifier: 25935702
author list: Bellmunt J, Orsola A, Sonpavde G
published in: European urology
information resource reference: Precision and predictive medicine in urothelial cancer: are we making progress? Eur Urol. 2015 Oct; 68(4):547-9.
journal title abbreviation: Eur Urol
publication date: 2015-04-29T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer?
PubMed Identifier: 26350576
author list: Fay AP, Bellmunt J
published in: BJU international
information resource reference: Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer? BJU Int. 2015 Oct; 116(4):500-1.
journal title abbreviation: BJU Int
publication date: 2015-10-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

New advances in genitourinary cancer: evidence gathered in 2014.
PubMed Identifier: 26227584
author list: Suárez C, Puente J, Gallardo E, Méndez-Vidal MJ, Climent MA, León L, Olmos D, García del Muro X, González-Billalabeitia E, Grande E, Bellmunt J, Mellado B, Maroto P, González del Alba A
published in: Cancer metastasis reviews
information resource reference: New advances in genitourinary cancer: evidence gathered in 2014. Cancer Metastasis Rev. 2015 Sep; 34(3):443-64.
journal title abbreviation: Cancer Metastasis Rev
publication date: 2015-09-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 9844
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?

Authorship 412950
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line.

Authorship 42716
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Endobronchial metastatic disease: analysis of 32 cases.

Authorship 847192
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Diagnosis of Bladder Carcinoma: A Clinician's Perspective.

Authorship 848452
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010.

Diagnosis of Bladder Carcinoma: A Clinician's Perspective.
PubMed Identifier: 26612221
author list: Harshman LC, Preston MA, Bellmunt J, Beard C
published in: Surgical pathology clinics
information resource reference: Diagnosis of Bladder Carcinoma: A Clinician's Perspective. Surg Pathol Clin. 2015 Dec; 8(4):677-85.
journal title abbreviation: Surg Pathol Clin
publication date: 2015-12-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 532904
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Wilms' tumor in an adult patient.

Authorship 853806
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.

Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
PubMed Identifier: 26487582
author list: Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, Bellmunt J, Necchi A
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016 Jan; 27(1):49-61.
journal title abbreviation: Ann Oncol
publication date: 2015-10-20T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 44742
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Fatal septic thrombophlebitis due to Salmonella enteritidis.

Authorship 856218
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.

Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.
PubMed Identifier: 26589768
author list: de Velasco G, Krajewski KM, Albiges L, Awad MM, Bellmunt J, Hodi FS, Choueiri TK
published in: Cancer immunology research
information resource reference: Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2016 Jan; 4(1):12-7.
journal title abbreviation: Cancer Immunol Res
publication date: 2015-11-20T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 49796
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [Bilateral choroidal metastasis as a form of presentation of pulmonary carcinoma].

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
PubMed Identifier: 26831717
author list: Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen E, Krajewski KM, Porta C, Pal S, Bellmunt J, McDermott DF, Heng DYC, Gray KP, Signoretti S
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452.
journal title abbreviation: Clin Cancer Res
publication date: 2016-02-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 869273
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: The evolving role of enzalutamide on the treatment of prostate cancer.

Authorship 863564
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

Authorship 870563
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/63646321

Authorship 869481
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.

https://connects.catalyst.harvard.edu/Profiles/profile/63646321
PubMed Identifier: 26673352
author list: De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su WC, Albiges L, Lin CC, Senkus-Konefka E, Flechon A, Mourey L, Necchi A, Loidl WC, Retz MM, Vaissière N, Culine S
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol. 2016 Mar; 27(3):449-54.
journal title abbreviation: Ann Oncol
publication date: 2015-12-16T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
PubMed Identifier: 26685010
author list: Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, Rathkopf DE, Fizazi K, Kantoff PW, Li J, Azad AA, Eigl BJ, Heng DY, Joshua AM, de Bono JS, Scher HI
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016 Mar; 27(3):454-60.
journal title abbreviation: Ann Oncol
publication date: 2015-12-18T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
PubMed Identifier: 26292040
author list: Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, Di Lorenzo G, Bellmunt J
published in: The Journal of urology
information resource reference: Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol. 2016 Feb; 195(2):277-82.
journal title abbreviation: J Urol
publication date: 2015-08-17T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

The evolving role of enzalutamide on the treatment of prostate cancer.
PubMed Identifier: 26839021
author list: Nadal R, Bellmunt J
published in: Future oncology (London, England)
information resource reference: The evolving role of enzalutamide on the treatment of prostate cancer. Future Oncol. 2016 Mar; 12(5):607-16.
journal title abbreviation: Future Oncol
publication date: 2016-02-03T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 94208
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.

Authorship 872354
type: Authorship
author rank in publication: 15
linked author: Bellmunt Molins, Joaquin
linked information resource: Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.

Authorship 871505
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/64184219

Authorship 871558
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?

Authorship 871489
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.

Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?
PubMed Identifier: 26497920
author list: Sonpavde G, Bellmunt J
published in: European urology
information resource reference: Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business? Eur Urol. 2016 Apr; 69(4):574-575.
journal title abbreviation: Eur Urol
publication date: 2015-10-21T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
PubMed Identifier: 26264159
author list: Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Bellmunt J
published in: European urology
information resource reference: Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr; 69(4):634-641.
journal title abbreviation: Eur Urol
publication date: 2015-08-08T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/64184219
PubMed Identifier: 26415779
author list: Sonpavde G, Pond GR, Bellmunt J
published in: European urology
information resource reference: Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr; 69(4):644-645.
journal title abbreviation: Eur Urol
publication date: 2015-09-26T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma.

The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
PubMed Identifier: 26497923
author list: Giannatempo P, Pond GR, Sonpavde G, Raggi D, Naik G, Galsky MD, Bellmunt J, Necchi A
published in: European urology
information resource reference: The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Apr; 69(4):624-633.
journal title abbreviation: Eur Urol
publication date: 2015-10-21T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 40367
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Predictive modelling in hormone-refractory prostate cancer (HRPC).

Authorship 42373
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.

Authorship 881088
type: Authorship
author rank in publication: 14
linked author: Bellmunt Molins, Joaquin
linked information resource: Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.

Authorship 526938
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.

Authorship 883051
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
PubMed Identifier: 26952546
author list: Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R
published in: Lancet (London, England)
information resource reference: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 07; 387(10031):1909-20.
journal title abbreviation: Lancet
publication date: 2016-03-04T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 884524
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma.

Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma.
PubMed Identifier: 27071455
author list: Sonpavde G, Bellmunt J
published in: Nature reviews. Urology
information resource reference: Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma. Nat Rev Urol. 2016 06; 13(6):306-7.
journal title abbreviation: Nat Rev Urol
publication date: 2016-04-13T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 886371
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles.

Authorship 886019
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.
PubMed Identifier: 27283319
author list: Mullane SA, Werner L, Rosenberg J, Signoretti S, Callea M, Choueiri TK, Freeman GJ, Bellmunt J
published in: Scientific reports
information resource reference: Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep. 2016 06 10; 6:27702.
journal title abbreviation: Sci Rep
publication date: 2016-06-10T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles.
PubMed Identifier: 27111282
author list: Cejas P, Li L, O'Neill NK, Duarte M, Rao P, Bowden M, Zhou CW, Mendiola M, Burgos E, Feliu J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW
published in: Nature medicine
information resource reference: Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nat Med. 2016 06; 22(6):685-91.
journal title abbreviation: Nat Med
publication date: 2016-04-25T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 887218
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.

Authorship 886600
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.

Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
PubMed Identifier: 26691493
author list: van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N
published in: European urology
information resource reference: Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. Eur Urol. 2016 05; 69(5):802-20.
journal title abbreviation: Eur Urol
publication date: 2015-12-12T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
PubMed Identifier: 26508309
author list: Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S
published in: European urology
information resource reference: Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 05; 69(5):924-32.
journal title abbreviation: Eur Urol
publication date: 2015-10-24T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base.
PubMed Identifier: 27269944
author list: Seisen T, Sun M, Leow JJ, Preston MA, Cole AP, Gelpi-Hammerschmidt F, Hanna N, Meyer CP, Kibel AS, Lipsitz SR, Nguyen PL, Bellmunt J, Choueiri TK, Trinh QD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
journal title abbreviation: J Clin Oncol
publication date: 2016-10-10T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 888861
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Urothelial carcinoma management in elderly or unfit patients.

Authorship 889472
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
PubMed Identifier: 27351382
author list: Bellmunt J, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, Choueiri TK, Orsola A, Takeda DY, Hahn WC, Kim J, Sonpavde G, Bowden M
published in: British journal of cancer
information resource reference: Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 06 28; 115(1):12-9.
journal title abbreviation: Br J Cancer
publication date: 2016-06-23T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Urothelial carcinoma management in elderly or unfit patients.
PubMed Identifier: 27358584
author list: Bellmunt J, Mottet N, De Santis M
published in: EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]
information resource reference: Urothelial carcinoma management in elderly or unfit patients. EJC Suppl. 2016 Mar; 14(1):1-20.
journal title abbreviation: EJC Suppl
publication date: 2016-03-22T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

McGregor, Bradley
eCommons Login: BM185
first name: Bradley
last name: McGregor
full name: Bradley McGregor, M.D.
has faculty rank: Assistant Professor
Person ID: 150559
person in primary position: Assistant Professor of Medicine
type: Agent
type: Person
preferred title: Assistant Professor of Medicine

Assistant Professor
sort order: 2
type: Faculty Rank

Associate Professor
sort order: 1
type: Faculty Rank

Full Professor
sort order: 0
type: Faculty Rank

Instructor
sort order: 4
type: Faculty Rank

Authorship 7472
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.

Authorship 84170
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity.

Authorship 891712
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
PubMed Identifier: 27407122
author list: Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016 07; 14(7):820-4.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2016-07-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 894618
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

Authorship 895078
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.

Authorship 894613
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
PubMed Identifier: 27198170
author list: McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK
published in: Cancer
information resource reference: A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 01; 122(15):2389-98.
journal title abbreviation: Cancer
publication date: 2016-05-19T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
PubMed Identifier: 26778300
author list: Mullane SA, Werner L, Guancial EA, Lis RT, Stack EC, Loda M, Kantoff PW, Choueiri TK, Rosenberg J, Bellmunt J
published in: Clinical genitourinary cancer
information resource reference: Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):352-9.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2015-12-24T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.
PubMed Identifier: 26778006
author list: Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL
published in: Clinical genitourinary cancer
information resource reference: Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2015-12-17T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 897272
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7.

Authorship 896886
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.

Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7.
PubMed Identifier: 26852077
author list: Mullane SA, Bellmunt J
published in: European urology
information resource reference: Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7. Eur Urol. 2016 09; 70(3):e71.
journal title abbreviation: Eur Urol
publication date: 2016-02-03T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
PubMed Identifier: 27310333
author list: Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE
published in: JAMA oncology
information resource reference: Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016 Aug 01; 2(8):1094-6.
journal title abbreviation: JAMA Oncol
publication date: 2016-08-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 561259
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Current vaccination strategies for prostate cancer.

Mossanen, Matthew
eCommons Login: MM679
first name: Matthew
last name: Mossanen
full name: Matthew Mossanen, M.D.
has faculty rank: Associate Professor
Person ID: 146390
person in primary position: Associate Professor of Surgery
type: Agent
type: Person
preferred title: Associate Professor of Surgery

Authorship 572755
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Chemotherapy for metastatic or unresectable bladder cancer.

Authorship 917655
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Cancer immunotherapy: new applications in urologic oncology.

Cancer immunotherapy: new applications in urologic oncology.
PubMed Identifier: 27584023
author list: Mullane SA, Bellmunt J
published in: Current opinion in urology
information resource reference: Cancer immunotherapy: new applications in urologic oncology. Curr Opin Urol. 2016 11; 26(6):556-63.
journal title abbreviation: Curr Opin Urol
publication date: 2016-11-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 69500
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.

Authorship 72072
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: [Symptomatic hypomagnesemia in a patient treated with cisplatin].

Authorship 393845
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Endobronchial metastases in colorectal adenocarcinoma.

Authorship 920263
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.

Authorship 928176
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/69406306

Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
PubMed Identifier: 27700015
author list: Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, Bellmunt J
published in: BJU international
information resource reference: Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. BJU Int. 2017 04; 119(4):579-584.
journal title abbreviation: BJU Int
publication date: 2016-10-26T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/69406306
PubMed Identifier: 27726966
author list: Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L
published in: European urology
information resource reference: Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017 02; 71(2):281-289.
journal title abbreviation: Eur Urol
publication date: 2016-10-08T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Authorship 471901
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: New chemotherapy combinations for advanced bladder cancer.

Authorship 932874
type: Authorship
author rank in publication: 18
linked author: Bellmunt Molins, Joaquin
linked information resource: Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.

Authorship 934069
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/70167951

Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
PubMed Identifier: 27262369
author list: Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A, Giannatempo P, Raggi D, Matsumoto K, Choueiri TK, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, Bellmunt J
published in: Clinical genitourinary cancer
information resource reference: Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 12; 14(6):494-498.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2016-05-12T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/70167951
PubMed Identifier: 27806880
author list: Orsola A, Mullane SA, Bellmunt J
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016; 64:127-136. Eur J Cancer. 2016 11; 68:196-197.
journal title abbreviation: Eur J Cancer
publication date: 2016-10-30T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016; 64:127-136.

Authorship 939424
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma.

Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma.
PubMed Identifier: 27912971
author list: Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Rouprêt M, Leow JJ, Vetterlein MW, Sun M, Alanee S, Choueiri TK, Trinh QD, Menon M, Abdollah F
published in: European urology
information resource reference: Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol. 2017 05; 71(5):714-718.
journal title abbreviation: Eur Urol
publication date: 2016-11-29T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 291550
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Chemotherapy for older patients with prostate cancer.

Authorship 345464
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.

Authorship 942915
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry.

Authorship 942824
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC).

Authorship 940723
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71516808

Authorship 942826
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study.

Authorship 940853
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authorship 940691
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Differential protein expression profiling by iTRAQ-2DLC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene.

Authorship 940852
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71516510

Authorship 941029
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.

Authorship 942051
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Discovery of the methylation of the metastasis suppressor gene KiSS-1 in bladder cancer.

Authorship 944107
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71516865

Untitled Publication
PubMed Identifier: 27969110
author list: Seisen T, Sun M, Lipsitz S, Abdollah F, Leow J, Menon M, Preston M, Harshman L, Kibel A, Nguyen P, Bellmunt J, Choueiri T, Trinh Q
published in: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
information resource reference: Prog Urol. 2016 Nov; 26(13):674-675.
journal title abbreviation: Prog Urol
publication date: 2016-10-27T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Untitled Publication
PubMed Identifier: 27969114
author list: Seisen T, Krasnow R, Rouprêt M, Lipsitz S, Leow J, Vetterlein M, Preston M, Kibel A, Choueiri T, Bellmunt J, Trinh Q, Chang S
published in: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
information resource reference: Prog Urol. 2016 Nov; 26(13):676-677.
journal title abbreviation: Prog Urol
publication date: 2016-10-27T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
PubMed Identifier: 28000388
author list: Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, De Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY
published in: Cancer medicine
information resource reference: Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Med. 2017 01; 6(1):186-194.
journal title abbreviation: Cancer Med
publication date: 2016-12-20T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC).
PubMed Identifier: 27962907
author list: Escudier BJ, Bellmunt J, Negrier S, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2009 May 20; 27(15_suppl):5020.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study.
PubMed Identifier: 27963000
author list: Hutson TE, Bellmunt J, Porta C, Staehler M, Szczylik C, Nadel A, Anderson S, Bukowski RM, Eisen T, Escudier B
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Long-term safety of sorafenib (SOR) for the treatment (tx) of advanced clear-cell renal-cell carcinoma (RCC): Data analysis from patients (pts) treated for over 1 year in the phase III TARGET study. J Clin Oncol. 2009 May 20; 27(15_suppl):e16057.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
PubMed Identifier: 27939400
author list: Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF
published in: Lancet (London, England)
information resource reference: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 01 07; 389(10064):67-76.
journal title abbreviation: Lancet
publication date: 2016-12-08T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry.
PubMed Identifier: 27962917
author list: Guix M, Lema L, Lloreta J, Rojo F, Suárez C, Carles J, de la Cruz J, Sánchez-Carbayo M, Albanell J, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry. J Clin Oncol. 2009 May 20; 27(15_suppl):5025.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/71516510
PubMed Identifier: 27937445
author list: Paz-Ares LG, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, Hevia M, de la Rosa F, Guillem V, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol. 2010 Jun 20; 28(18_suppl):LBA4518.
journal title abbreviation: J Clin Oncol
publication date: 2010-06-20T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study.

Discovery of the methylation of the metastasis suppressor gene KiSS-1 in bladder cancer.
PubMed Identifier: 27962918
author list: Sanchez-Carbayo M, Orenes E, Gil M, Piulats JM, Alvarez M, Bellmunt J, Palou J, Cordon-Cardo C, Ecke T, Lopez-Beltran A
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Discovery of the methylation of the metastasis suppressor gene KiSS-1 in bladder cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):5023.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Differential protein expression profiling by iTRAQ-2DLC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene.
PubMed Identifier: 27963025
author list: Grau L, Ruppen I, Gil M, Piulats JM, Bellmunt J, Ashman K, Ecke T, Sanchez-Carbayo M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Differential protein expression profiling by iTRAQ-2DLC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene. J Clin Oncol. 2009 May 20; 27(15_suppl):e16043.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/71516808
PubMed Identifier: 27937444
author list: De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy MG, Daugaard G, Gil T, Maroto JP, Marreaud S, Sylvester R
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. J Clin Oncol. 2010 Jun 20; 28(18_suppl):LBA4519.
journal title abbreviation: J Clin Oncol
publication date: 2010-06-20T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986.

https://connects.catalyst.harvard.edu/Profiles/profile/71516865
PubMed Identifier: 27962942
author list: Bellmunt J, Trigo J, Calvo E, Carles J, Perez-Gracia J, Rubió J, Virizuela J, López R, Lázaro M, Albanell J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (mRCC): A phase II study of sorafenib, gemcitabine (Gem), and metronomic capecitabine (Cap) in patients with advanced mRCC (SOGUG-02-06). J Clin Oncol. 2009 May 20; 27(15_suppl):5040.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (mRCC): A phase II study of sorafenib, gemcitabine (Gem), and metronomic capecitabine (Cap) in patients with advanced mRCC (SOGUG-02-06).

Authorship 945759
type: Authorship
author rank in publication: 20
linked author: Bellmunt Molins, Joaquin
linked information resource: Identification of a novel urothelial carcinoma (UC) biomarker of lethality.

Authorship 944840
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Identification of ALK gene alterations in urothelial carcinoma (UC).

Authorship 945090
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Nailfold capillary microscopy and bleomycin-induced vascular toxicity.

Authorship 945729
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Untitled Publication

Authorship 945781
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.

Authorship 945037
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-a2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Authorship 945190
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.

Authorship 945211
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.

Authorship 945260
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Cytologic diagnosis in bronchoalveolar lavage specimens. A diagnostic technique for lung neoplasmas with a peripheral location.

Authorship 944608
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.

Authorship 944645
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Molecular markers of the mTOR pathway activation in human tumors: A baseline analysis.

Authorship 945519
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: Relationship of duration of androgen blockade and response to antiandrogen withdrawal: A retrospective study.

Authorship 944653
type: Authorship
author rank in publication: 17
linked author: Bellmunt Molins, Joaquin
linked information resource: ALK chromosomal alterations in neuroendocrine tumors.

Authorship 944908
type: Authorship
author rank in publication: 12
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma.

Authorship 944823
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

Authorship 945161
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Authorship 945003
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: Untitled Publication

Authorship 945799
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71645764

Authorship 945940
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: [Acromegaly and lung cancer].

Identification of a novel urothelial carcinoma (UC) biomarker of lethality.
PubMed Identifier: 28023354
author list: Rosenberg JE, Werner L, Selvarajah S, Weir B, Regan MM, Jacobus SJ, Berman DM, Schutz FA, O'Brien R, Choueiri TK, Barretina J, Signoretti S, Loda M, Guancial EA, Gallardo E, Rojo FG, Lloreta J, Hahn WC, Kantoff PW, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Identification of a novel urothelial carcinoma (UC) biomarker of lethality. J Clin Oncol. 2011 May 20; 29(15_suppl):4569.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Nailfold capillary microscopy and bleomycin-induced vascular toxicity.
PubMed Identifier: 1705473
author list: Bellmunt J, Knobel H, Navarro M, Jolis L
published in: Cancer investigation
information resource reference: Nailfold capillary microscopy and bleomycin-induced vascular toxicity. Cancer Invest. 1990; 8(6):641.
journal title abbreviation: Cancer Invest
publication date: 1990-01-01T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
PubMed Identifier: 27522164
author list: Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, Wiechno PJ, Liu K, Waldman MF, Gandhi A, Barton D, Jungnelius U, Fandi A, Sternberg CN, Petrylak DP
published in: European urology
information resource reference: Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2017 02; 71(2):168-171.
journal title abbreviation: Eur Urol
publication date: 2016-08-10T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/71645764
PubMed Identifier: 28023377
author list: Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, Gonzalez Del Alba A, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodriguez de Antona C
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group. J Clin Oncol. 2011 May 20; 29(15_suppl):4559.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group.

ALK chromosomal alterations in neuroendocrine tumors.
PubMed Identifier: 28021948
author list: Montagut C, Arriola E, Galvan AB, Rojo FG, Salido M, Gallen M, Garcia M, Martinez A, Pons F, Servitja S, Iglesias M, Menendez S, Serrano S, Sole F, Rovira A, Albanell J, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: ALK chromosomal alterations in neuroendocrine tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):10585.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
PubMed Identifier: 28016042
author list: Font A, Esteban E, Carles J, Climent MA, Gonzalez-Larriba JL, Berrocal A, Bellmunt J, Garcia-Ribas I, Marfa X, Fabregat X
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4544.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-a2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).
PubMed Identifier: 28023396
author list: Melichar B, Bracarda S, Matveev V, Rusakov I, Kaprin A, Zyryanov A, Janciauskiene R, Fernebro E, Mickisch GH, Gore ME, Schulze A, Jethwa S, Sneller V, Mulders P, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-a2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2011 May 20; 29(15_suppl):4546.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
PubMed Identifier: 28023314
author list: Krajewski KM, Fougeray R, Choueiri TK, Pons F, Schutz FA, Rosenberg JE, Salhi Y, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. J Clin Oncol. 2011 May 20; 29(15_suppl):4570.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Relationship of duration of androgen blockade and response to antiandrogen withdrawal: A retrospective study.
PubMed Identifier: 28021127
author list: Nunez I, Suarez C, Morales R, Gallén M, Planas J, Maldonado X, Valverde CM, Serrano C, Morote J, Bellmunt J, Carles J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Relationship of duration of androgen blockade and response to antiandrogen withdrawal: A retrospective study. J Clin Oncol. 2011 May 20; 29(15_suppl):e15104.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular markers of the mTOR pathway activation in human tumors: A baseline analysis.
PubMed Identifier: 28016835
author list: Rojo F, Iglesias C, Tabernero J, Jimenez J, Rodriguez S, Bellmunt J, Ramon S, Baselga J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Molecular markers of the mTOR pathway activation in human tumors: A baseline analysis. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9524.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Cytologic diagnosis in bronchoalveolar lavage specimens. A diagnostic technique for lung neoplasmas with a peripheral location.
PubMed Identifier: 2376199
author list: Bellmunt J, De Gracia J, Morales S, Orriols R, Tallada N
published in: Chest
information resource reference: Cytologic diagnosis in bronchoalveolar lavage specimens. A diagnostic technique for lung neoplasmas with a peripheral location. Chest. 1990 Aug; 98(2):513-4.
journal title abbreviation: Chest
publication date: 1990-08-01T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of ALK gene alterations in urothelial carcinoma (UC).
PubMed Identifier: 28023357
author list: Bellmunt J, Selvarajah S, Rodig S, Salido M, Costa I, Bellosillo B, Werner L, Namgyal C, Schutz FA, Pons F, O'Brien R, Barretina J, Signoretti S, Loda M, Albanell J, Choueiri TK, Berman DM, Kantoff PW, Rosenberg JE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Identification of ALK gene alterations in urothelial carcinoma (UC). J Clin Oncol. 2011 May 20; 29(15_suppl):4568.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
PubMed Identifier: 28020585
author list: Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. J Clin Oncol. 2011 May 20; 29(15_suppl):e15027.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma.
PubMed Identifier: 28020452
author list: Suarez C, Gallardo E, Rodon Ahnert J, Guix M, Bonfill T, Pons F, Beltran M, Moya I, Galtes S, Albanell J, Carles J, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma. J Clin Oncol. 2011 May 20; 29(15_suppl):e15095.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.
PubMed Identifier: 27376138
author list: Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ
published in: Bladder cancer (Amsterdam, Netherlands)
information resource reference: Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202.
journal title abbreviation: Bladder Cancer
publication date: 2016-04-27T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

[Acromegaly and lung cancer].
PubMed Identifier: 2756227
author list: Morales S, Navarro M, Bellmunt J, Jolis L
published in: Revista clinica espanola
information resource reference: [Acromegaly and lung cancer]. Rev Clin Esp. 1989 Apr; 184(6):337-8.
journal title abbreviation: Rev Clin Esp
publication date: 1989-04-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
PubMed Identifier: 27560549
author list: de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R
published in: JAMA oncology
information resource reference: Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. JAMA Oncol. 2017 Jan 01; 3(1):68-75.
journal title abbreviation: JAMA Oncol
publication date: 2017-01-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 947063
type: Authorship
author rank in publication: 7
linked author: Bellmunt Molins, Joaquin
linked information resource: Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.

Authorship 946848
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma.

Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma.
PubMed Identifier: 28045620
author list: Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, Vetterlein MW, Preston MA, Hanna N, Kibel AS, Sun M, Choueiri TK, Trinh QD, Chang SL
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Mar 10; 35(8):852-860.
journal title abbreviation: J Clin Oncol
publication date: 2017-01-03T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.
PubMed Identifier: 28035321
author list: Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, Bellmunt J, Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang AZ, Nielsen ME, Smith AB, Milowsky MI
published in: Bladder cancer (Amsterdam, Netherlands)
information resource reference: Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer. Bladder Cancer. 2016 Oct 27; 2(4):405-413.
journal title abbreviation: Bladder Cancer
publication date: 2016-10-27T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 949062
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
PubMed Identifier: 28081914
author list: Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, Lunceford J, Saraf S, Perini RF, O'Donnell PH
published in: The Lancet. Oncology
information resource reference: Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017 Feb; 18(2):212-220.
journal title abbreviation: Lancet Oncol
publication date: 2017-01-10T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 951578
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Authorship 952949
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.

Strategies to design clinical studies to identify predictive biomarkers in cancer research.
PubMed Identifier: 28088073
author list: Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I
published in: Cancer treatment reviews
information resource reference: Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat Rev. 2017 Feb; 53:79-97.
journal title abbreviation: Cancer Treat Rev
publication date: 2016-12-30T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
PubMed Identifier: 28126351
author list: Fossati N, Willemse PM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S
published in: European urology
information resource reference: The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. 2017 07; 72(1):84-109.
journal title abbreviation: Eur Urol
publication date: 2017-01-24T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 954804
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study.

Authorship 954098
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC).

Authorship 953784
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).

Authorship 954926
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.

Authorship 955826
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).

Authorship 954401
type: Authorship
author rank in publication: 14
linked author: Bellmunt Molins, Joaquin
linked information resource: Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel.

Authorship 955276
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.

Authorship 955521
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Genomic characterization of metastatic urothelial carcinoma.

Authorship 955204
type: Authorship
author rank in publication: 13
linked author: Bellmunt Molins, Joaquin
linked information resource: Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy.

Authorship 955885
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.

Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
PubMed Identifier: 27324051
author list: Necchi A, Pond GR, Raggi D, Giannatempo P, Vogelzang NJ, Grivas P, Galsky MD, Bellmunt J, Sonpavde G
published in: Clinical genitourinary cancer
information resource reference: Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2017 02; 15(1):23-30.e2.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2016-05-27T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study.
PubMed Identifier: 28143295
author list: Martin Liberal J, Maroto JP, Mellado B, Ferrer F, Sancho G, Rovirosa A, Vigues F, Palou J, Ribal MJ, Bellmunt J, Garcia Del Muro X
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study. J Clin Oncol. 2012 Feb 10; 30(5_suppl):270.
journal title abbreviation: J Clin Oncol
publication date: 2012-02-10T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).
PubMed Identifier: 28136860
author list: Werner L, Bellmunt J, Nikitas N, Stack EC, Lis R, Signoretti S, Loda M, Regan MM, Park RS, O'Brien R, Berman DM, Bamias A, Rosenberg JE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):260.
journal title abbreviation: J Clin Oncol
publication date: 2013-02-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.
PubMed Identifier: 28136933
author list: Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, De Bono JS, Paliwal P, Durham S, Cheng S, Logothetis C
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. J Clin Oncol. 2013 Feb 20; 31(6_suppl):LBA8.
journal title abbreviation: J Clin Oncol
publication date: 2013-02-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy.
PubMed Identifier: 28143170
author list: Guancial EA, Werner L, Stack E, Lis R, Signoretti S, Loda M, Gallardo E, Rojo F, Lloreta J, Regan MM, Park R, O'Brien R, Berman DM, Bellmunt J, Rosenberg JE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy. J Clin Oncol. 2012 Feb 10; 30(5_suppl):291.
journal title abbreviation: J Clin Oncol
publication date: 2012-02-10T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC).
PubMed Identifier: 28136741
author list: Iyer G, Riester M, Werner L, Schultz N, Stack EC, Park R, Loda M, Ostrovnaya I, Kantoff PW, Bajorin DF, Solit DB, Michor F, Bellmunt J, Rosenberg JE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):279.
journal title abbreviation: J Clin Oncol
publication date: 2013-02-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).
PubMed Identifier: 28137132
author list: Agarwal N, Bellmunt J, Choueiri TK, Qu AQ, Fougeray R, Niegisch G, Galsky MD, Wong YN, Stadler WM, Sridhar SS, Sternberg CN, Sonpavde G
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):301.
journal title abbreviation: J Clin Oncol
publication date: 2013-02-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Genomic characterization of metastatic urothelial carcinoma.
PubMed Identifier: 28136803
author list: Riester M, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Rosenberg JE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Genomic characterization of metastatic urothelial carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):247.
journal title abbreviation: J Clin Oncol
publication date: 2013-02-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
PubMed Identifier: 28137924
author list: Teo MY, Bambury RM, Zabor EC, Jordan E, Al-Ahmadie H, Boyd ME, Bouvier N, Mullane SA, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clin Cancer Res. 2017 Jul 15; 23(14):3610-3618.
journal title abbreviation: Clin Cancer Res
publication date: 2017-01-30T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel.
PubMed Identifier: 28143241
author list: Duran I, Montagut C, Calvo E, Galtes S, Navarrete A, Rodriguez-Pascual J, Hidalgo M, Rodriguez-Moreno JF, Cubillo A, Garcia A, Sanchez L, Barbas C, Viqueira A, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel. J Clin Oncol. 2012 Feb 10; 30(5_suppl):250.
journal title abbreviation: J Clin Oncol
publication date: 2012-02-10T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 956249
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.

The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
PubMed Identifier: 27637910
author list: Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, Ladoire S, Wong YN, Alva AS, Rosenberg JE, Galsky MD, Yu EY
published in: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
information resource reference: The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clin Appl Thromb Hemost. 2017 Oct; 23(7):755-760.
journal title abbreviation: Clin Appl Thromb Hemost
publication date: 2016-09-16T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 958387
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.

Authorship 958557
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
PubMed Identifier: 28214651
author list: Bellmunt J, Powles T, Vogelzang NJ
published in: Cancer treatment reviews
information resource reference: A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat Rev. 2017 Mar; 54:58-67.
journal title abbreviation: Cancer Treat Rev
publication date: 2017-02-02T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
PubMed Identifier: 28220024
author list: de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK
published in: The oncologist
information resource reference: Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist. 2017 03; 22(3):286-292.
journal title abbreviation: Oncologist
publication date: 2017-02-20T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
PubMed Identifier: 9060963
author list: Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA
published in: Journal of the National Cancer Institute
information resource reference: Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst. 1997 Mar 05; 89(5):395-6.
journal title abbreviation: J Natl Cancer Inst
publication date: 1997-03-05T00:00:00
year: 1997
type: Academic Article
type: Article
type: Document
type: Information Resource

Nail-fold capillary microscopy and chemotherapy-induced vascular toxicity.
PubMed Identifier: 1714294
author list: Bellmunt J, Morales S, Albanell J, Gallego O
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Nail-fold capillary microscopy and chemotherapy-induced vascular toxicity. Ann Oncol. 1991 Apr; 2(4):310.
journal title abbreviation: Ann Oncol
publication date: 1991-04-01T00:00:00
year: 1991
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
PubMed Identifier: 12850530
author list: Bellmunt J, Hussain M, Dinney CP
published in: Critical reviews in oncology/hematology
information resource reference: Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S85-104.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2003-06-27T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

[Pulmonary metastasising benign leiomyoma evolving to chronic respiratory failure].
PubMed Identifier: 9379773
author list: Salud A, Porcel JM, Vidal-Pla R, Bellmunt J
published in: Medicina clinica
information resource reference: [Pulmonary metastasising benign leiomyoma evolving to chronic respiratory failure]. Med Clin (Barc). 1997 Sep 20; 109(9):358.
journal title abbreviation: Med Clin (Barc)
publication date: 1997-09-20T00:00:00
year: 1997
type: Academic Article
type: Article
type: Document
type: Information Resource

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
PubMed Identifier: 9469328
author list: Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998 Feb; 16(2):453-61.
journal title abbreviation: J Clin Oncol
publication date: 1998-02-01T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
PubMed Identifier: 10908844
author list: Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Albanell J, Tabernero JM, Cortés-Funes H, Baselga J
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer. 2000 Jul; 36 Suppl 2:17-25.
journal title abbreviation: Eur J Cancer
publication date: 2000-07-01T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 959086
type: Authorship
author rank in publication: 12
linked author: Bellmunt Molins, Joaquin
linked information resource: Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base.

[Antineoplastic chemotherapy in digestive tumors].
PubMed Identifier: 1720494
author list: Bellmunt J, Albanell J, Gallego OS, Vicente P
published in: Medicina clinica
information resource reference: [Antineoplastic chemotherapy in digestive tumors]. Med Clin (Barc). 1991 Sep 21; 97(9):358.
journal title abbreviation: Med Clin (Barc)
publication date: 1991-09-21T00:00:00
year: 1991
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 960082
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Authorship 960002
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Authorship 963013
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease.

Authorship 961133
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients.

Authorship 961122
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC).

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
PubMed Identifier: 27591931
author list: Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N
published in: European urology
information resource reference: EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2017 04; 71(4):630-642.
journal title abbreviation: Eur Urol
publication date: 2016-08-31T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
PubMed Identifier: 27568654
author list: Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P
published in: European urology
information resource reference: EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 04; 71(4):618-629.
journal title abbreviation: Eur Urol
publication date: 2016-08-25T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease.
PubMed Identifier: 27043218
author list: Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A
published in: World journal of urology
information resource reference: Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol. 2017 Mar; 35(3):327-335.
journal title abbreviation: World J Urol
publication date: 2016-04-04T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients.
PubMed Identifier: 27946906
author list: Bellmunt J, Trigo JM, Garcia-Ribas I, Roca JM, Galtes S, Perez-Romero A, de la Cruz JJ, Tabernero JM, Alba E, Baselga J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients. J Clin Oncol. 2005 Jun; 23(16_suppl):2067.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC).
PubMed Identifier: 27946985
author list: de Bono JS, Bellmunt J, Droz JP, Miller K, Zugmaier G, Sternberg C, Gimenez V, Parker C, Mason M, Graham J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC). J Clin Oncol. 2005 Jun; 23(16_suppl):4609.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 967230
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Authorship 968228
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
PubMed Identifier: 28246107
author list: De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK
published in: Cancer immunology research
information resource reference: Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017 04; 5(4):312-318.
journal title abbreviation: Cancer Immunol Res
publication date: 2017-02-28T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
PubMed Identifier: 28212060
author list: Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF
published in: The New England journal of medicine
information resource reference: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 03 16; 376(11):1015-1026.
journal title abbreviation: N Engl J Med
publication date: 2017-02-17T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

[Spinal cord compression as a primary manifestation of occult thyroid carcinoma].
PubMed Identifier: 1633237
author list: Vicente P, Rovirosa A, Gallego O, Albanell J, Bellmunt J, Solé LA
published in: Anales de medicina interna (Madrid, Spain : 1984)
information resource reference: [Spinal cord compression as a primary manifestation of occult thyroid carcinoma]. An Med Interna. 1992 Jul; 9(7):334-6.
journal title abbreviation: An Med Interna
publication date: 1992-07-01T00:00:00
year: 1992
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
PubMed Identifier: 18538178
author list: Bellmunt J, Delgado FM, George C
published in: Seminars in oncology
information resource reference: Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Semin Oncol. 2008 Jun; 35(3 Suppl 3):S34-43.
journal title abbreviation: Semin Oncol
publication date: 2008-06-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents.
PubMed Identifier: 18640849
author list: Bellmunt J, Albiol S, Suárez C, Albanell J
published in: Critical reviews in oncology/hematology
information resource reference: Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol. 2009 Mar; 69(3):211-22.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2008-07-21T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 972606
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/77085285

https://connects.catalyst.harvard.edu/Profiles/profile/77085285
PubMed Identifier: 28336078
author list: Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O
published in: European urology
information resource reference: What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017 08; 72(2):250-266.
journal title abbreviation: Eur Urol
publication date: 2017-03-21T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource
label: What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.
PubMed Identifier: 1525774
author list: Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, De Torres J, Morote J, Lopez M, Solé LA
published in: Cancer
information resource reference: Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer. 1992 Oct 01; 70(7):1974-9.
journal title abbreviation: Cancer
publication date: 1992-10-01T00:00:00
year: 1992
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 976593
type: Authorship
author rank in publication: 21
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/77880944

https://connects.catalyst.harvard.edu/Profiles/profile/77880944
PubMed Identifier: 28389316
author list: García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, González Del Alba A, Castellano D, Gallardo E, Anido U, García Del Muro X, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J
published in: The Lancet. Oncology
information resource reference: Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. Lancet Oncol. 2017 05; 18(5):672-681a.
journal title abbreviation: Lancet Oncol
publication date: 2017-04-04T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.

Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule.
PubMed Identifier: 9490086
author list: Ribas A, Albanell J, Bellmunt J, Bermejo B, Gallardo E, Vera R, Bodi R, Solé-Calvo LA
published in: Acta oncologica (Stockholm, Sweden)
information resource reference: Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule. Acta Oncol. 1997; 36(7):701-4.
journal title abbreviation: Acta Oncol
publication date: 1997-01-01T00:00:00
year: 1997
type: Academic Article
type: Article
type: Document
type: Information Resource

[Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].
PubMed Identifier: 1666192
author list: Navarro M, Mur E, Jolis L, Bellmunt J, Bodi R, Solé LA, Rubio D
published in: Revista clinica espanola
information resource reference: [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung]. Rev Clin Esp. 1991 Oct; 189(5):209-12.
journal title abbreviation: Rev Clin Esp
publication date: 1991-10-01T00:00:00
year: 1991
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 978316
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).

Authorship 978124
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.

Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
PubMed Identifier: 28412065
author list: Seisen T, Sun M, Lipsitz SR, Abdollah F, Leow JJ, Menon M, Preston MA, Harshman LC, Kibel AS, Nguyen PL, Bellmunt J, Choueiri TK, Trinh QD
published in: European urology
information resource reference: Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
journal title abbreviation: Eur Urol
publication date: 2017-04-12T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
PubMed Identifier: 28419193
author list: Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera MB, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh AJM, Pujol E, Perez-Gracia JL, González Larriba JL, Collado R, Los M, Maciá S, De Wit R
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Ann Oncol. 2017 Jul 01; 28(7):1517-1522.
journal title abbreviation: Ann Oncol
publication date: 2017-07-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

[Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide].
PubMed Identifier: 1352640
author list: Albanell J, Gallego OS, Bellmunt J, Vicente P, Morales S, Solé LA
published in: Revista clinica espanola
information resource reference: [Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide]. Rev Clin Esp. 1992 May; 190(9):463-5.
journal title abbreviation: Rev Clin Esp
publication date: 1992-05-01T00:00:00
year: 1992
type: Academic Article
type: Article
type: Document
type: Information Resource

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
PubMed Identifier: 9366300
author list: Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Solé LA, Baselga J
published in: Cancer
information resource reference: Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997 Nov 15; 80(10):1966-72.
journal title abbreviation: Cancer
publication date: 1997-11-15T00:00:00
year: 1997
type: Academic Article
type: Article
type: Document
type: Information Resource

Endobronchial metastases in colorectal adenocarcinoma.
PubMed Identifier: 1466085
author list: Rovirosa Casino A, Bellmunt J, Salud A, Vicente P, Maldonado J, Bodi R, Salvador L
published in: Tumori
information resource reference: Endobronchial metastases in colorectal adenocarcinoma. Tumori. 1992 Aug 31; 78(4):270-3.
journal title abbreviation: Tumori
publication date: 1992-08-31T00:00:00
year: 1992
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
PubMed Identifier: 20656473
author list: Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowski R, Eisen T, Escudier B
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer. 2010 Sep; 46(13):2432-40.
journal title abbreviation: Eur J Cancer
publication date: 2010-07-23T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls.
PubMed Identifier: 21278220
author list: Bellmunt J, Choueiri TK, Schutz FA, Rosenberg JE
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. Ann Oncol. 2011 Feb; 22(2):245-7.
journal title abbreviation: Ann Oncol
publication date: 2011-02-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

450 Brookline Ave
type: Address
address line 1: Dana-Farber Cancer Institute
address line 2: Yawkey 11
address line 3: 450 Brookline Ave
city: Boston
postal code: 02215
state or province: MA

Recommendations for the optimal management of early and advanced urothelial carcinoma.
PubMed Identifier: 22116017
author list: Castellano D, Carles J, Esteban E, Trigo JM, Climent MÁ, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz JÁ, Bellmunt J
published in: Cancer treatment reviews
information resource reference: Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treat Rev. 2012 Aug; 38(5):431-41.
journal title abbreviation: Cancer Treat Rev
publication date: 2011-11-23T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
PubMed Identifier: 22270724
author list: Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri S, Somasekar S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J
published in: Nature medicine
information resource reference: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Jan 22; 18(2):221-3.
journal title abbreviation: Nat Med
publication date: 2012-01-22T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
PubMed Identifier: 22917984
author list: Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI
published in: European urology
information resource reference: ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66.
journal title abbreviation: Eur Urol
publication date: 2012-08-14T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal.
PubMed Identifier: 12180225
author list: Morote J, Bellmunt J
published in: European urology
information resource reference: Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal. Eur Urol. 2002 Mar; 41(3):257-61.
journal title abbreviation: Eur Urol
publication date: 2002-03-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
PubMed Identifier: 17229776
author list: Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, Baselga J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007 Mar; 18(3):522-8.
journal title abbreviation: Ann Oncol
publication date: 2007-01-17T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
PubMed Identifier: 10986057
author list: Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, Sáenz A, López-Brea M, Font A, Nogué M, Bastús R, Climent MA, de la Cruz JJ, Albanell J, Banús JM, Gallardo E, Diaz-Rubio E, Cortés-Funes H, Baselga J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol. 2000 Sep 15; 18(18):3247-55.
journal title abbreviation: J Clin Oncol
publication date: 2000-09-15T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.
PubMed Identifier: 11677109
author list: Bellmunt J, de Wit R, Albanell J, Baselga J
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer. 2001 Nov; 37(17):2212-5.
journal title abbreviation: Eur J Cancer
publication date: 2001-11-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

[The clinical importance of the fibroblast growth factor (bFGF) as a biological marker and therapeutic modulator. Future applications].
PubMed Identifier: 8965493
author list: Eres N, Bellmunt J
published in: Medicina clinica
information resource reference: [The clinical importance of the fibroblast growth factor (bFGF) as a biological marker and therapeutic modulator. Future applications]. Med Clin (Barc). 1996 Sep 14; 107(8):296-8.
journal title abbreviation: Med Clin (Barc)
publication date: 1996-09-14T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

Interferon and disseminated Langerhans cell histiocytosis.
PubMed Identifier: 1608357
author list: Bellmunt J, Albanell J, Salud A, Español T, Morales S, Solé-Calvo LA
published in: Medical and pediatric oncology
information resource reference: Interferon and disseminated Langerhans cell histiocytosis. Med Pediatr Oncol. 1992; 20(4):336-7.
journal title abbreviation: Med Pediatr Oncol
publication date: 1992-01-01T00:00:00
year: 1992
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 981926
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.

Authorship 981227
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.

Authorship 980817
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.

Authorship 983199
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.

Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
PubMed Identifier: 28493171
author list: Farina MS, Lundgren KT, Bellmunt J
published in: Drugs
information resource reference: Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs. 2017 Jul; 77(10):1077-1089.
journal title abbreviation: Drugs
publication date: 2017-07-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.
PubMed Identifier: 28478885
author list: Necchi A, Raggi D, Giannatempo P, Sonpavde G, Galsky MD, Bellmunt J, Mariani L, Miceli R
published in: Clinical genitourinary cancer
information resource reference: From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clin Genitourin Cancer. 2017 10; 15(5):509-512.e9.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2017-04-13T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
PubMed Identifier: 28487100
author list: Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J
published in: The Journal of urology
information resource reference: Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. J Urol. 2017 10; 198(4):817-823.
journal title abbreviation: J Urol
publication date: 2017-05-06T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
PubMed Identifier: 28478043
author list: Fonteyne V, Ost P, Bellmunt J, Droz JP, Mongiat-Artus P, Inman B, Paillaud E, Saad F, Ploussard G
published in: European urology
information resource reference: Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. Eur Urol. 2018 01; 73(1):40-50.
journal title abbreviation: Eur Urol
publication date: 2017-05-03T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
PubMed Identifier: 12197223
author list: Bellmunt J, Cos J, Clèries R, Pérez M, Ribas A, Eres N, Murio JE, Margarit C, Baselga J
published in: Cancer investigation
information resource reference: Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 2002; 20(5-6):673-85.
journal title abbreviation: Cancer Invest
publication date: 2002-01-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

[Peripheral cholangiocarcinoma: results of surgical treatment].
PubMed Identifier: 16584691
author list: Margarit C, Escartín A, Bellmunt J, Allende E, Bilbao I
published in: Gastroenterologia y hepatologia
information resource reference: [Peripheral cholangiocarcinoma: results of surgical treatment]. Gastroenterol Hepatol. 2006 Apr; 29(4):215-23.
journal title abbreviation: Gastroenterol Hepatol
publication date: 2006-04-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity.
PubMed Identifier: 1688509
author list: Bellmunt J, Navarro M, Morales S, Jolis L, Carulla J, Knobell H, Vilardell M, Sole LA
published in: Cancer
information resource reference: Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity. Cancer. 1990 Jan 15; 65(2):303-9.
journal title abbreviation: Cancer
publication date: 1990-01-15T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
PubMed Identifier: 9219513
author list: Bellmunt J, Eres N, Ribas A, Casado S, Albanell J, Baselga J
published in: Cancer chemotherapy and pharmacology
information resource reference: Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. Cancer Chemother Pharmacol. 1997; 40(3):273-6.
journal title abbreviation: Cancer Chemother Pharmacol
publication date: 1997-01-01T00:00:00
year: 1997
type: Academic Article
type: Article
type: Document
type: Information Resource

Chemotherapy for older patients with prostate cancer.
PubMed Identifier: 16981902
author list: Anderson J, Van Poppel H, Bellmunt J, Miller K, Droz JP, Fitzpatrick JM
published in: BJU international
information resource reference: Chemotherapy for older patients with prostate cancer. BJU Int. 2007 Feb; 99(2):269-73.
journal title abbreviation: BJU Int
publication date: 2006-09-18T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 987216
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Pembrolizumab for Advanced Urothelial Carcinoma.

Pembrolizumab for Advanced Urothelial Carcinoma.
PubMed Identifier: 28591526
author list: Bellmunt J, Bajorin DF
published in: The New England journal of medicine
information resource reference: Pembrolizumab for Advanced Urothelial Carcinoma. N Engl J Med. 2017 06 08; 376(23):2304.
journal title abbreviation: N Engl J Med
publication date: 2017-06-08T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

The medical management of prostate cancer: a multidisciplinary team approach.
PubMed Identifier: 16956362
author list: Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM
published in: BJU international
information resource reference: The medical management of prostate cancer: a multidisciplinary team approach. BJU Int. 2007 Jan; 99(1):22-7.
journal title abbreviation: BJU Int
publication date: 2006-09-06T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Addison's disease secondary to prostatic carcinoma. A case report.
PubMed Identifier: 2284701
author list: Navarro M, Felip E, Garcia L, Bellmunt J, Jolis L, Morales S, Rubio D
published in: Tumori
information resource reference: Addison's disease secondary to prostatic carcinoma. A case report. Tumori. 1990 Dec 31; 76(6):611-3.
journal title abbreviation: Tumori
publication date: 1990-12-31T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
PubMed Identifier: 17235043
author list: de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol. 2007 Jan 20; 25(3):257-62.
journal title abbreviation: J Clin Oncol
publication date: 2007-01-20T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Sunitinib in renal-cell carcinoma: expanded indications.
PubMed Identifier: 19615941
author list: Choueiri TK, Bellmunt J
published in: The Lancet. Oncology
information resource reference: Sunitinib in renal-cell carcinoma: expanded indications. Lancet Oncol. 2009 Aug; 10(8):740.
journal title abbreviation: Lancet Oncol
publication date: 2009-07-15T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

New drugs and new approaches in metastatic bladder cancer.
PubMed Identifier: 12900012
author list: Bellmunt J, de Wit R, Albiol S, Tabernero J, Albanell J, Baselga J
published in: Critical reviews in oncology/hematology
information resource reference: New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003 Aug; 47(2):195-206.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2003-08-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
PubMed Identifier: 22677572
author list: Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G
published in: European urology
information resource reference: A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep; 62(3):523-33.
journal title abbreviation: Eur Urol
publication date: 2012-06-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

EORTC-GU group expert opinion on metastatic renal cell cancer.
PubMed Identifier: 19157861
author list: de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009 Mar; 45(5):765-73.
journal title abbreviation: Eur J Cancer
publication date: 2009-01-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

[New cell target treatments: indications, results and tolerance].
PubMed Identifier: 19658316
author list: Bellmunt J, Gelabert-Mas A
published in: Actas urologicas espanolas
information resource reference: [New cell target treatments: indications, results and tolerance]. Actas Urol Esp. 2009 May; 33(5):609-14.
journal title abbreviation: Actas Urol Esp
publication date: 2009-05-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

European early phase II dose-finding study of droloxifene in advanced breast cancer.
PubMed Identifier: 1962595
author list: Bellmunt J, Solé L
published in: American journal of clinical oncology
information resource reference: European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol. 1991; 14 Suppl 2:S36-9.
journal title abbreviation: Am J Clin Oncol
publication date: 1991-01-01T00:00:00
year: 1991
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 997924
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma.

A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma.
PubMed Identifier: 28690523
author list: Ramírez de Olano A, Bellmunt J, Rodrigo A, Álvarez L, Terrádez A, García-Foncillas J, Laes JF
published in: Case reports in oncology
information resource reference: A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma. Case Rep Oncol. 2017 May-Aug; 10(2):493-500.
journal title abbreviation: Case Rep Oncol
publication date: 2017-06-09T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/857241
PubMed Identifier: 19687335
author list: Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20; 27(27):4454-61.
journal title abbreviation: J Clin Oncol
publication date: 2009-08-17T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

[Corticoid treatment in Castleman's disease].
PubMed Identifier: 8523950
author list: Ribas A, Bellmunt J, Solé LA, Ribas-Mundó M
published in: Medicina clinica
information resource reference: [Corticoid treatment in Castleman's disease]. Med Clin (Barc). 1995 Nov 11; 105(16):638-9.
journal title abbreviation: Med Clin (Barc)
publication date: 1995-11-11T00:00:00
year: 1995
type: Academic Article
type: Article
type: Document
type: Information Resource

Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.
PubMed Identifier: 22257100
author list: Bahl A, Bellmunt J, Oudard S
published in: BJU international
information resource reference: Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. BJU Int. 2012 Mar; 109 Suppl 2:14-9.
journal title abbreviation: BJU Int
publication date: 2012-03-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

The optimize project: beyond first-line therapy in metastatic renal cell carcinoma.
PubMed Identifier: 22767406
author list: Castellano D, Bellmunt J
published in: Cancer metastasis reviews
information resource reference: The optimize project: beyond first-line therapy in metastatic renal cell carcinoma. Cancer Metastasis Rev. 2012 Sep; 31 Suppl 1:S1-2.
journal title abbreviation: Cancer Metastasis Rev
publication date: 2012-09-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?
PubMed Identifier: 18778888
author list: Bellmunt J
published in: European urology
information resource reference: Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol. 2009 Jun; 55(6):1310-2.
journal title abbreviation: Eur Urol
publication date: 2008-09-02T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Toxicities of targeted therapy and their management in kidney cancer.
PubMed Identifier: 21277078
author list: Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C
published in: European urology
information resource reference: Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011 Apr; 59(4):526-40.
journal title abbreviation: Eur Urol
publication date: 2011-01-14T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
PubMed Identifier: 21315502
author list: Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A
published in: European urology
information resource reference: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011 Apr; 59(4):572-83.
journal title abbreviation: Eur Urol
publication date: 2011-01-25T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.
PubMed Identifier: 20231303
author list: Martin-Broto J, Gutierrez A, Garcia-Del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande LM, Lainez N, Maurel J, De Juan A, Losa F, Andres R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gomez-España A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol. 2010 Jul; 21(7):1552-1557.
journal title abbreviation: Ann Oncol
publication date: 2010-03-15T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
PubMed Identifier: 22176867
author list: Krajewski KM, Fougeray R, Bellmunt J, Pons F, Schutz FA, Rosenberg JE, Salhi Y, Choueiri TK
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 2012 Jul; 48(10):1495-502.
journal title abbreviation: Eur J Cancer
publication date: 2011-12-14T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1006255
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/87485313

Authorship 1000817
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.

Authorship 1007649
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.

Authorship 1001316
type: Authorship
author rank in publication: 24
linked author: Bellmunt Molins, Joaquin
linked information resource: Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.

Authorship 1002758
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Authorship 1006978
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Authorship 1004600
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
PubMed Identifier: 28815048
author list: Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE
published in: Journal for immunotherapy of cancer
information resource reference: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017; 5:68.
journal title abbreviation: J Immunother Cancer
publication date: 2017-08-15T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
PubMed Identifier: 28837718
author list: Seisen T, Jamzadeh A, Leow JJ, Rouprêt M, Cole AP, Lipsitz SR, Kibel AS, Nguyen PL, Sun M, Menon M, Bellmunt J, Choueiri TK, Trinh QD
published in: JAMA oncology
information resource reference: Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
journal title abbreviation: JAMA Oncol
publication date: 2018-02-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
PubMed Identifier: 28807024
author list: Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE
published in: Journal for immunotherapy of cancer
information resource reference: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 08 15; 5(1):68.
journal title abbreviation: J Immunother Cancer
publication date: 2017-08-15T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.
PubMed Identifier: 28824940
author list: Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, O'Donnell M, Quale DZ
published in: Bladder cancer (Amsterdam, Netherlands)
information resource reference: Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer. 2017 Jul 27; 3(3):145-146.
journal title abbreviation: Bladder Cancer
publication date: 2017-07-27T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
PubMed Identifier: 28757301
author list: Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouvière O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L
published in: European urology
information resource reference: Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017 12; 72(6):869-885.
journal title abbreviation: Eur Urol
publication date: 2017-07-27T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.
PubMed Identifier: 28803034
author list: Leow JJ, Cole AP, Seisen T, Bellmunt J, Mossanen M, Menon M, Preston MA, Choueiri TK, Kibel AS, Chung BI, Sun M, Chang SL, Trinh QD
published in: European urology
information resource reference: Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. Eur Urol. 2018 Mar; 73(3):374-382.
journal title abbreviation: Eur Urol
publication date: 2017-08-10T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/87485313
PubMed Identifier: 28853615
author list: Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G
published in: Acta oncologica (Stockholm, Sweden)
information resource reference: Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta Oncol. 2018 Apr; 57(4):491-497.
journal title abbreviation: Acta Oncol
publication date: 2017-08-30T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).
PubMed Identifier: 20110291
author list: Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure Á, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol. 2010 Feb; 21(2):195-198.
journal title abbreviation: Ann Oncol
publication date: 2010-02-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
PubMed Identifier: 20368553
author list: Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010 May 01; 28(13):2144-50.
journal title abbreviation: J Clin Oncol
publication date: 2010-04-05T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up.
PubMed Identifier: 20555063
author list: Bellmunt J, Orsola A, Maldonado X, Kataja V
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May; 21 Suppl 5:v134-6.
journal title abbreviation: Ann Oncol
publication date: 2010-05-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy.
PubMed Identifier: 20963928
author list: Katz L, Choueiri TK, Bellmunt J
published in: BJU international
information resource reference: ¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy. BJU Int. 2010 Nov; 106(9):1249-50.
journal title abbreviation: BJU Int
publication date: 2010-11-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Variant forms of bladder cancer: basic considerations on treatment approaches.
PubMed Identifier: 21360040
author list: Pons F, Orsola A, Morote J, Bellmunt J
published in: Current oncology reports
information resource reference: Variant forms of bladder cancer: basic considerations on treatment approaches. Curr Oncol Rep. 2011 Jun; 13(3):216-21.
journal title abbreviation: Curr Oncol Rep
publication date: 2011-06-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1008497
type: Authorship
author rank in publication: 11
linked author: Bellmunt Molins, Joaquin
linked information resource: Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.

Authorship 1008587
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Upper tract urothelial carcinoma: a different disease entity in terms of management.

Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.
PubMed Identifier: 28864222
author list: Sevillano E, Werner L, Bossé D, Lalani AA, Wankowicz SAM, de Velasco G, Farina M, Lundgren K, Choueiri TK, González Del Alba A, Bellmunt J
published in: Clinical genitourinary cancer
information resource reference: Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis. Clin Genitourin Cancer. 2017 12; 15(6):e1089-e1094.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2017-08-02T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Upper tract urothelial carcinoma: a different disease entity in terms of management.
PubMed Identifier: 28848663
author list: Leow JJ, Chong KT, Chang SL, Bellmunt J
published in: ESMO open
information resource reference: Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open. 2016; 1(6):e000126.
journal title abbreviation: ESMO Open
publication date: 2017-01-24T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.
PubMed Identifier: 21930687
author list: Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2012 May; 23(5):1234-1240.
journal title abbreviation: Ann Oncol
publication date: 2011-09-19T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1010016
type: Authorship
author rank in publication: 12
linked author: Bellmunt Molins, Joaquin
linked information resource: Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer.

Authorship 1011040
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Antiangiogenesis to curb urothelial cancer.

Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer.
PubMed Identifier: 28899722
author list: Vetterlein MW, Seisen T, Leow JJ, Preston MA, Sun M, Friedlander DF, Meyer CP, Chun FK, Lipsitz SR, Menon M, Kibel AS, Bellmunt J, Choueiri TK, Trinh QD
published in: Clinical genitourinary cancer
information resource reference: Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clin Genitourin Cancer. 2017 Aug 24.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2017-08-24T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Antiangiogenesis to curb urothelial cancer.
PubMed Identifier: 28916369
author list: Bellmunt J
published in: Lancet (London, England)
information resource reference: Antiangiogenesis to curb urothelial cancer. Lancet. 2017 11 18; 390(10109):2220-2221.
journal title abbreviation: Lancet
publication date: 2017-09-12T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1012504
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: 'Working toward understanding oligo and polymetastatic prostate cancer'.

Authorship 1013171
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.

Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.
PubMed Identifier: 28923700
author list: Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY
published in: Clinical genitourinary cancer
information resource reference: Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clin Genitourin Cancer. 2017 Aug 24.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2017-08-24T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

'Working toward understanding oligo and polymetastatic prostate cancer'.
PubMed Identifier: 28922341
author list: Chapin BF, Bellmunt J
published in: Current opinion in urology
information resource reference: 'Working toward understanding oligo and polymetastatic prostate cancer'. Curr Opin Urol. 2017 11; 27(6):532.
journal title abbreviation: Curr Opin Urol
publication date: 2017-11-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.
PubMed Identifier: 18385198
author list: Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol. 2008 Aug; 19(8):1387-1392.
journal title abbreviation: Ann Oncol
publication date: 2008-04-02T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients.
PubMed Identifier: 19625182
author list: Bellmunt J, Macià F, Malmusi D, Llorente JA, Carles J, Lloreta J, Foro P, Gelabert A, Albanell J, Castells X
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. Eur J Cancer. 2009 Nov; 45(16):2804-9.
journal title abbreviation: Eur J Cancer
publication date: 2009-07-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
PubMed Identifier: 20231682
author list: Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010 Apr 10; 28(11):1850-5.
journal title abbreviation: J Clin Oncol
publication date: 2010-03-15T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
PubMed Identifier: 21524237
author list: Schutz FA, Bellmunt J, Rosenberg JE, Choueiri TK
published in: Expert opinion on drug safety
information resource reference: Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opin Drug Saf. 2011 Jul; 10(4):645-53.
journal title abbreviation: Expert Opin Drug Saf
publication date: 2011-04-28T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
PubMed Identifier: 21757258
author list: Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A
published in: Actas urologicas espanolas
information resource reference: [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Actas Urol Esp. 2011 Nov-Dec; 35(10):565-79.
journal title abbreviation: Actas Urol Esp
publication date: 2011-07-14T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Advances in the management of high-risk localised and metastatic prostate cancer.
PubMed Identifier: 22257099
author list: Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W
published in: BJU international
information resource reference: Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int. 2012 Mar; 109 Suppl 2:8-13.
journal title abbreviation: BJU Int
publication date: 2012-03-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1015141
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.

Authorship 1014562
type: Authorship
author rank in publication: 2
linked author: Bellmunt Molins, Joaquin
linked information resource: Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
PubMed Identifier: 28962591
author list: Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE
published in: Journal for immunotherapy of cancer
information resource reference: Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 09 28; 5(1):80.
journal title abbreviation: J Immunother Cancer
publication date: 2017-09-28T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.
PubMed Identifier: 28961845
author list: Bellmunt J, Eigl BJ, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar SS, Sternberg CN, Retz M, Pal S, Blumenstein B, Jacobs C, Stewart PS, Petrylak DP
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Ann Oncol. 2017 Oct 01; 28(10):2481-2488.
journal title abbreviation: Ann Oncol
publication date: 2017-10-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1016282
type: Authorship
author rank in publication: 16
linked author: Bellmunt Molins, Joaquin
linked information resource: Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

Authorship 1016071
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.
PubMed Identifier: 28753879
author list: Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD
published in: European urology focus
information resource reference: Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. Eur Urol Focus. 2018 12; 4(6):937-945.
journal title abbreviation: Eur Urol Focus
publication date: 2017-03-31T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
PubMed Identifier: 28967485
author list: Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J
published in: The Lancet. Oncology
information resource reference: First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 11; 18(11):1483-1492.
journal title abbreviation: Lancet Oncol
publication date: 2017-09-26T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
PubMed Identifier: 12209718
author list: Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J
published in: Cancer
information resource reference: Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002 Aug 15; 95(4):751-7.
journal title abbreviation: Cancer
publication date: 2002-08-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
PubMed Identifier: 28988769
author list: Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Weinstein JN, Kwiatkowski DJ, Lerner SP
published in: Cell
information resource reference: Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
journal title abbreviation: Cell
publication date: 2017-10-05T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1019377
type: Authorship
author rank in publication: 4
linked author: Bellmunt Molins, Joaquin
linked information resource: Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells.
PubMed Identifier: 18607069
author list: Hurtado A, Pinós T, Barbosa-Desongles A, López-Avilés S, Barquinero J, Petriz J, Santamaria-Martínez A, Morote J, de Torres I, Bellmunt J, Reventós J, Munell F
published in: Cellular oncology : the official journal of the International Society for Cellular Oncology
information resource reference: Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells. Cell Oncol. 2008; 30(4):349-65.
journal title abbreviation: Cell Oncol
publication date: 2008-01-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Predictive modelling in hormone-refractory prostate cancer (HRPC).
PubMed Identifier: 19211372
author list: Bellmunt J, Carles J, Albanell J
published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
information resource reference: Predictive modelling in hormone-refractory prostate cancer (HRPC). Clin Transl Oncol. 2009 Feb; 11(2):82-5.
journal title abbreviation: Clin Transl Oncol
publication date: 2009-02-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Experience with sorafenib and the elderly patient.
PubMed Identifier: 20043216
author list: Dutcher JP, Tannir N, Bellmunt J, Escudier B
published in: Medical oncology (Northwood, London, England)
information resource reference: Experience with sorafenib and the elderly patient. Med Oncol. 2010 Dec; 27(4):1359-70.
journal title abbreviation: Med Oncol
publication date: 2009-12-31T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1021277
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/91521726

https://connects.catalyst.harvard.edu/Profiles/profile/91521726
PubMed Identifier: 29059273
author list: Fizazi K, Ulys A, Sengeløv L, Moe M, Ladoire S, Thiery-Vuillemin A, Flechon A, Guida A, Bellmunt J, Climent MA, Chowdhury S, Dumez H, Matouskova M, Penel N, Liutkauskiene S, Stachurski L, Sternberg CN, Baton F, Germann N, Daugaard G
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. Ann Oncol. 2017 Nov 01; 28(11):2741-2746.
journal title abbreviation: Ann Oncol
publication date: 2017-11-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource
label: A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

https://connects.catalyst.harvard.edu/Profiles/profile/91522303
PubMed Identifier: 29077785
author list: Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Ann Oncol. 2018 02 01; 29(2):361-369.
journal title abbreviation: Ann Oncol
publication date: 2018-02-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

[Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult].
PubMed Identifier: 2325479
author list: Albanell J, Salud A, Bellmunt J, Español T, Morales S, García-Bragado F, Solé-Calvo LA
published in: Medicina clinica
information resource reference: [Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult]. Med Clin (Barc). 1990 Feb 10; 94(5):184-6.
journal title abbreviation: Med Clin (Barc)
publication date: 1990-02-10T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
PubMed Identifier: 21078050
author list: Bellmunt J, Eisen T, Szczylik C, Mulders P, Porta C
published in: BJU international
information resource reference: A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. 2011 Apr; 107(8):1190-9.
journal title abbreviation: BJU Int
publication date: 2010-11-15T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
PubMed Identifier: 21908503
author list: Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep; 22 Suppl 6:vi45-9.
journal title abbreviation: Ann Oncol
publication date: 2011-09-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Current vaccination strategies for prostate cancer.
PubMed Identifier: 22001436
author list: Joniau S, Abrahamsson PA, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S
published in: European urology
information resource reference: Current vaccination strategies for prostate cancer. Eur Urol. 2012 Feb; 61(2):290-306.
journal title abbreviation: Eur Urol
publication date: 2011-10-03T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.
PubMed Identifier: 22595043
author list: Morales-Barrera R, Bellmunt J, Suárez C, Valverde C, Guix M, Serrano C, Gallén M, Carles J
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer. 2012 Aug; 48(12):1816-21.
journal title abbreviation: Eur J Cancer
publication date: 2012-05-16T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

New perspectives in the therapy of castration resistant prostate cancer.
PubMed Identifier: 23043326
author list: Rescigno P, Buonerba C, Bellmunt J, Sonpavde G, De Placido S, Di Lorenzo G
published in: Current drug targets
information resource reference: New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets. 2012 Dec; 13(13):1676-86.
journal title abbreviation: Curr Drug Targets
publication date: 2012-12-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1025450
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review.

Authorship 1024699
type: Authorship
author rank in publication: 9
linked author: Bellmunt Molins, Joaquin
linked information resource: Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.

Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
PubMed Identifier: 28743155
author list: Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Löppenberg B, Chun FK, Menon M, Sun M, Barletta JA, Choueiri TK, Bellmunt J, Trinh QD, Preston MA
published in: Cancer
information resource reference: Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017 Nov 15; 123(22):4346-4355.
journal title abbreviation: Cancer
publication date: 2017-07-25T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review.
PubMed Identifier: 29121502
author list: Casadevall D, Kilian AY, Bellmunt J
published in: Cancer treatment reviews
information resource reference: The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review. Cancer Treat Rev. 2017 Dec; 61:82-93.
journal title abbreviation: Cancer Treat Rev
publication date: 2017-11-06T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Chemotherapy for metastatic or unresectable bladder cancer.
PubMed Identifier: 17382797
author list: Bellmunt J, Albiol S
published in: Seminars in oncology
information resource reference: Chemotherapy for metastatic or unresectable bladder cancer. Semin Oncol. 2007 Apr; 34(2):135-44.
journal title abbreviation: Semin Oncol
publication date: 2007-04-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1026255
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.
PubMed Identifier: 29137449
author list: Moreira RB, Debiasi M, Francini E, Nuzzo PV, Velasco G, Maluf FC, Fay AP, Bellmunt J, Choueiri TK, Schutz FA
published in: Oncotarget
information resource reference: Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 2017 Oct 13; 8(48):84572-84578.
journal title abbreviation: Oncotarget
publication date: 2017-08-08T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.
PubMed Identifier: 2347056
author list: Bellmunt J, Morales S, Navarro M, Solé LA
published in: Cancer chemotherapy and pharmacology
information resource reference: Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines. Cancer Chemother Pharmacol. 1990; 26 Suppl:S81-4.
journal title abbreviation: Cancer Chemother Pharmacol
publication date: 1990-01-01T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

[Advanced bladder cancer: new therapeutic strategies].
PubMed Identifier: 12570917
author list: Albiol S, Bellmunt J
published in: Medicina clinica
information resource reference: [Advanced bladder cancer: new therapeutic strategies]. Med Clin (Barc). 2003 Jan 25; 120(2):68-77.
journal title abbreviation: Med Clin (Barc)
publication date: 2003-01-25T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
PubMed Identifier: 20351323
author list: Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010 May 01; 28(13):2280-5.
journal title abbreviation: J Clin Oncol
publication date: 2010-03-29T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Overview of gemcitabine triplets in metastatic bladder cancer.
PubMed Identifier: 12604129
author list: de Wit R, Bellmunt J
published in: Critical reviews in oncology/hematology
information resource reference: Overview of gemcitabine triplets in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003 Feb; 45(2):191-7.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2003-02-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma.
PubMed Identifier: 15086915
author list: Vilà MR, Kaplan GG, Feigelstock D, Nadal M, Morote J, Porta R, Bellmunt J, Meseguer A
published in: Kidney international
information resource reference: Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney Int. 2004 May; 65(5):1761-73.
journal title abbreviation: Kidney Int
publication date: 2004-05-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1028332
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.

Authorship 1027993
type: Authorship
author rank in publication: 5
linked author: Bellmunt Molins, Joaquin
linked information resource: Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.

Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
PubMed Identifier: 29158104
author list: Moschini M, Shariat SF, Rouprêt M, De Santis M, Bellmunt J, Sternberg CN, Tombal B, Collette L
published in: The Journal of urology
information resource reference: Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. J Urol. 2018 05; 199(5):1149-1157.
journal title abbreviation: J Urol
publication date: 2017-11-20T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.
PubMed Identifier: 29158079
author list: Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD
published in: Clinical genitourinary cancer
information resource reference: Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clin Genitourin Cancer. 2018 04; 16(2):e483-e490.
journal title abbreviation: Clin Genitourin Cancer
publication date: 2017-11-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
PubMed Identifier: 20960029
author list: Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, Bellmunt J, del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanovic A, Cortes-Funes H, Buesa JM
published in: Investigational new drugs
information resource reference: Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs. 2012 Apr; 30(2):729-40.
journal title abbreviation: Invest New Drugs
publication date: 2010-10-20T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/934013
PubMed Identifier: 21427062
author list: Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011 Dec; 22(12):2646-2653.
journal title abbreviation: Ann Oncol
publication date: 2011-03-21T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].
PubMed Identifier: 21757259
author list: Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F
published in: Actas urologicas espanolas
information resource reference: [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. Actas Urol Esp. 2011 Oct; 35(9):501-14.
journal title abbreviation: Actas Urol Esp
publication date: 2011-07-14T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

What are the expected developments in the medical treatment of bladder cancer.
PubMed Identifier: 21943989
author list: Bellmunt J
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: What are the expected developments in the medical treatment of bladder cancer. Eur J Cancer. 2011 Sep; 47 Suppl 3:S294-7.
journal title abbreviation: Eur J Cancer
publication date: 2011-09-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
PubMed Identifier: 15710949
author list: Tabernero J, Rojo F, Marimón I, Voi M, Albanell J, Guix M, Vázquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, García M, Valverde S, Baselga J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2005 Apr 10; 23(11):2521-33.
journal title abbreviation: J Clin Oncol
publication date: 2005-02-14T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/935490
PubMed Identifier: 22162575
author list: De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012 Jan 10; 30(2):191-9.
journal title abbreviation: J Clin Oncol
publication date: 2011-12-12T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
PubMed Identifier: 16807437
author list: Bellmunt J, Albiol S, de Olano AR, Pujadas J, Maroto P
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol. 2006 May; 17 Suppl 5:v113-7.
journal title abbreviation: Ann Oncol
publication date: 2006-05-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce.
PubMed Identifier: 18774306
author list: Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M
published in: Critical reviews in oncology/hematology
information resource reference: The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009 Jan; 69(1):64-72.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2008-09-05T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

[Glycoprotein P and resistance to antitumor chemotherapy].
PubMed Identifier: 7906748
author list: Vicente P, Bellmunt J, de Torres I
published in: Medicina clinica
information resource reference: [Glycoprotein P and resistance to antitumor chemotherapy]. Med Clin (Barc). 1993 Dec 11; 101(20):785-8.
journal title abbreviation: Med Clin (Barc)
publication date: 1993-12-11T00:00:00
year: 1993
type: Academic Article
type: Article
type: Document
type: Information Resource

[Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases].
PubMed Identifier: 8061135
author list: Bellmunt J, Ribas A, Ocaña I, Capdevila JA, Ruiz-Marcellan MC, Giralt J, Sole LA
published in: Anales de medicina interna (Madrid, Spain : 1984)
information resource reference: [Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases]. An Med Interna. 1994 May; 11(5):217-23.
journal title abbreviation: An Med Interna
publication date: 1994-05-01T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

[Current strategies in the treatment of renal-cell cancer: targeted therapies].
PubMed Identifier: 18381031
author list: Trigo JM, Bellmunt J
published in: Medicina clinica
information resource reference: [Current strategies in the treatment of renal-cell cancer: targeted therapies]. Med Clin (Barc). 2008 Mar 22; 130(10):380-92.
journal title abbreviation: Med Clin (Barc)
publication date: 2008-03-22T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
PubMed Identifier: 18456766
author list: Bellmunt J, Albiol S, Kataja V
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May; 19 Suppl 2:ii47-8.
journal title abbreviation: Ann Oncol
publication date: 2008-05-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1032293
type: Authorship
author rank in publication: 1
linked author: Bellmunt Molins, Joaquin
linked information resource: Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma.

Authorship 1031652
type: Authorship
author rank in publication: 22
linked author: Bellmunt Molins, Joaquin
linked information resource: Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.

Authorship 1031747
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: Pembrolizumab in the treatment of advanced urothelial cancer.

Authorship 1032281
type: Authorship
author rank in publication: 6
linked author: Bellmunt Molins, Joaquin
linked information resource: ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.

Authorship 1033042
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Pembrolizumab in the treatment of advanced urothelial cancer.
PubMed Identifier: 29219016
author list: Lundgren KT, Farina MS, Bellmunt J
published in: Future oncology (London, England)
information resource reference: Pembrolizumab in the treatment of advanced urothelial cancer. Future Oncol. 2017 Dec; 13(30):2745-2758.
journal title abbreviation: Future Oncol
publication date: 2017-09-12T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
PubMed Identifier: 29259186
author list: Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, Chen DYT, Alpaugh RK, Hoffman-Censits J, Garraway LA, Getz G, Carter SL, Bellmunt J, Plimack ER, Rosenberg JE, Van Allen EM
published in: Nature communications
information resource reference: Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017 12 19; 8(1):2193.
journal title abbreviation: Nat Commun
publication date: 2017-12-19T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.
PubMed Identifier: 28753897
author list: Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K
published in: European urology focus
information resource reference: Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus. 2019 03; 5(2):242-249.
journal title abbreviation: Eur Urol Focus
publication date: 2017-06-03T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma.
PubMed Identifier: 29203837
author list: Bellmunt J, Nadal R
published in: Nature reviews. Clinical oncology
information resource reference: Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma. Nat Rev Clin Oncol. 2018 02; 15(2):73-74.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2017-12-05T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis.
PubMed Identifier: 29198325
author list: Urun Y, Leow JJ, Fay AP, Albiges L, Choueiri TK, Bellmunt J
published in: Critical reviews in oncology/hematology
information resource reference: ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Dec; 120:120-126.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2017-11-02T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.
PubMed Identifier: 19635642
author list: Bellmunt J, Rosenberg JE, Choueiri TK
published in: European urology
information resource reference: Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol. 2009 Oct; 56(4):606-8.
journal title abbreviation: Eur Urol
publication date: 2009-07-22T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.
PubMed Identifier: 21689888
author list: Escudier B, Osanto S, Ljungberg B, Porta C, Wagstaff J, Mulders P, Gore M, Bex A, Bellmunt J, Bracarda S, Franklin A, Honoré PH, Ravaud A, Steijn Jv, Aziz Z, Akaza H
published in: Cancer treatment reviews
information resource reference: Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treat Rev. 2012 Apr; 38(2):127-32.
journal title abbreviation: Cancer Treat Rev
publication date: 2012-04-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1035594
type: Authorship
author rank in publication: 10
linked author: Bellmunt Molins, Joaquin
linked information resource: Comparative effectiveness of robot-assisted vs. open radical cystectomy.

Comparative effectiveness of robot-assisted vs. open radical cystectomy.
PubMed Identifier: 29277584
author list: Hanna N, Leow JJ, Sun M, Friedlander DF, Seisen T, Abdollah F, Lipsitz SR, Menon M, Kibel AS, Bellmunt J, Choueiri TK, Trinh QD
published in: Urologic oncology
information resource reference: Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol. 2018 03; 36(3):88.e1-88.e9.
journal title abbreviation: Urol Oncol
publication date: 2017-12-23T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/954825
PubMed Identifier: 19786668
author list: De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol. 2009 Nov 20; 27(33):5634-9.
journal title abbreviation: J Clin Oncol
publication date: 2009-09-28T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.
PubMed Identifier: 19819078
author list: Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P
published in: Cancer treatment reviews
information resource reference: Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 2010 Feb; 36(1):16-23.
journal title abbreviation: Cancer Treat Rev
publication date: 2009-10-09T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations.
PubMed Identifier: 20640588
author list: Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba JL, Esteban E, López R, Paz-Ares L, Bellmunt J, Castellano D
published in: Cancer metastasis reviews
information resource reference: Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer Metastasis Rev. 2010 Aug; 29 Suppl 1:11-20.
journal title abbreviation: Cancer Metastasis Rev
publication date: 2010-08-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.
PubMed Identifier: 21376284
author list: Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J
published in: The Lancet. Oncology
information resource reference: A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar; 12(3):211-4.
journal title abbreviation: Lancet Oncol
publication date: 2011-03-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
PubMed Identifier: 21763973
author list: Appleby L, Morrissey S, Bellmunt J, Rosenberg J
published in: Hematology/oncology clinics of North America
information resource reference: Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. Hematol Oncol Clin North Am. 2011 Aug; 25(4):893-915.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2011-08-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil.
PubMed Identifier: 3400123
author list: Bellmunt J, Navarro M, Hidalgo R, Solé LA
published in: Tumori
information resource reference: Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. Tumori. 1988 Jun 30; 74(3):329-31.
journal title abbreviation: Tumori
publication date: 1988-06-30T00:00:00
year: 1988
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/965173
PubMed Identifier: 20942831
author list: Bracarda S, Bellmunt J, Melichar B, Négrier S, Bajetta E, Ravaud A, Sneller V, Escudier B
published in: BJU international
information resource reference: Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-a2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 2011 Jan; 107(2):214-9.
journal title abbreviation: BJU Int
publication date: 2010-10-13T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-a2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.

Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.
PubMed Identifier: 21652581
author list: Pera M, Gallego R, Montagut C, Martín-Richard M, Iglesias M, Conill C, Reig A, Balagué C, Pétriz L, Momblan D, Bellmunt J, Maurel J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol. 2012 Mar; 23(3):664-670.
journal title abbreviation: Ann Oncol
publication date: 2011-06-07T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Castration-resistant prostate cancer: new science and therapeutic prospects.
PubMed Identifier: 21789134
author list: Bellmunt J, Oh WK
published in: Therapeutic advances in medical oncology
information resource reference: Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol. 2010 May; 2(3):189-207.
journal title abbreviation: Ther Adv Med Oncol
publication date: 2010-05-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1040805
type: Authorship
author rank in publication: 8
linked author: Bellmunt Molins, Joaquin
linked information resource: Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.
PubMed Identifier: 29353553
author list: Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK
published in: Journal for immunotherapy of cancer
information resource reference: Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018 01 22; 6(1):5.
journal title abbreviation: J Immunother Cancer
publication date: 2018-01-22T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Mitomycin-C and vinblastine in advanced breast cancer.
PubMed Identifier: 2497417
author list: Navarro M, Bellmunt J, Balañá C, Colomer R, Jolis L, del Campo JM
published in: Oncology
information resource reference: Mitomycin-C and vinblastine in advanced breast cancer. Oncology. 1989; 46(3):137-42.
journal title abbreviation: Oncology
publication date: 1989-01-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Future developments in renal cell carcinoma.
PubMed Identifier: 19430003
author list: Bellmunt J
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Future developments in renal cell carcinoma. Ann Oncol. 2009 May; 20 Suppl 1:i13-17.
journal title abbreviation: Ann Oncol
publication date: 2009-05-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
PubMed Identifier: 20234366
author list: Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J
published in: British journal of cancer
information resource reference: Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Br J Cancer. 2010 Mar 30; 102(7):1137-44.
journal title abbreviation: Br J Cancer
publication date: 2010-03-16T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
PubMed Identifier: 20593250
author list: Beck J, Bellmunt J, Escudier B
published in: Medical oncology (Northwood, London, England)
information resource reference: Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study. Med Oncol. 2011 Dec; 28(4):1379-83.
journal title abbreviation: Med Oncol
publication date: 2010-07-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1042031
type: Authorship
author rank in publication: 3
linked author: Bellmunt Molins, Joaquin
linked information resource: New treatment options for metastatic renal cell carcinoma.

New treatment options for metastatic renal cell carcinoma.
PubMed Identifier: 28761748
author list: Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH
published in: ESMO open
information resource reference: New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017; 2(2):e000185.
journal title abbreviation: ESMO Open
publication date: 2017-05-09T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

[Regulatory proteins of the cell cycle: alterations in the cycline D1 pathway as a paradigm. Findings in breast cancer].
PubMed Identifier: 9859095
author list: Eres N, Bellmunt J
published in: Medicina clinica
information resource reference: [Regulatory proteins of the cell cycle: alterations in the cycline D1 pathway as a paradigm. Findings in breast cancer]. Med Clin (Barc). 1998 Nov 07; 111(15):592-6.
journal title abbreviation: Med Clin (Barc)
publication date: 1998-11-07T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

New therapeutic challenges in advanced bladder cancer.
PubMed Identifier: 23040256
author list: Bellmunt J, Petrylak DP
published in: Seminars in oncology
information resource reference: New therapeutic challenges in advanced bladder cancer. Semin Oncol. 2012 Oct; 39(5):598-607.
journal title abbreviation: Semin Oncol
publication date: 2012-10-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource